You must be a current COE Member and logged into your account to view this content.
Don’t have an account? Sign up.
You must be a current COE Member and logged into your account to view this content.
Don’t have an account? Sign up.
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Meghan McHugh |
| Title | manager lung screening program |
| meghan.mchugh@aah.org | |
| Phone | (920)-461-4043 |
| User ID | Meghan McHugh |
| Facility ID | 2184 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Meghan McHugh |
| Title | manager lung screening program |
| meghan.mchugh@aah.org | |
| Phone | (920)-461-4043 |
| User ID | Meghan McHugh |
| Facility ID | 2186 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Meghan McHugh |
| Title | manager lung screening program |
| meghan.mchugh@aah.org | |
| Phone | (920)-461-4043 |
| User ID | Meghan McHugh |
| Facility ID | 2187 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Meghan McHugh |
| Title | manager lung screening program |
| meghan.mchugh@aah.org | |
| Phone | (920)-461-4043 |
| User ID | Meghan McHugh |
| Facility ID | 2181 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Meghan McHugh |
| Title | Manager lung screening program |
| meghan.mchugh@aah.org | |
| Phone | (920)-461-4043 |
| User ID | Meghan McHugh |
| Facility ID | 2188 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Meghan McHugh |
| Title | Manager lung screening program |
| meghan.mchugh@aah.org | |
| Phone | (920)-461-4043 |
| User ID | Meghan McHugh |
| Facility ID | 2183 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Meghan McHugh |
| Title | Manager Lung Screening program |
| meghan.mchugh@aah.org | |
| Phone | (920)-461-4043 |
| User ID | Meghan McHugh |
| Facility ID | 2182 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Meghan McHugh |
| Title | Manager Lung Screening Program |
| meghan.mchugh@aah.org | |
| Phone | (920)-461-4043 |
| User ID | Meghan McHugh |
| Facility ID | 2185 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Yaron Perry |
| Title | Chief Division of Thoracic Surgery |
| yperry@buffalo.edu | |
| Phone | (912)-414-7273 |
| User ID | Yaron Perry |
| Facility ID | 1934 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| Comments | Verify pack year and age. Our team has an IRB approved clinical trial open for accrual for those between the ages of 40-49 with a 20-pack year smoking history. |
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Darcy Doege |
| Title | RN Clinical Supervisor |
| darcy.doege@advocatehealth.org | |
| Phone | (913)-424-6431 |
| User ID | Darcy Doege |
| Facility ID | 1557 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Katherine Jacobson |
| Title | Practice Manager |
| katherine@pulmpro.com | |
| Phone | (818)-282-3667 |
| User ID | Katherine Jacobson |
| Facility ID | 2180 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Katherine Jacobson |
| Title | Practice Manager |
| katherine@pulmpro.com | |
| Phone | (818)-282-3667 |
| User ID | Katherine Jacobson |
| Facility ID | 2180 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Comments | Utilizing Fleischner Society Criteria on radiology reports |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Comments | Any incidental nodule either suspicious appearing 8mm are discussed during a bi-weekly Pulmonary Multidisciplinary Conference attending by interventional pulmonology, radiology, and thoracic surgery |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Comments | All patients are called for any detected nodules for follow up imaging or referral for biopsy, notes are written in VA EHR with primary care provider attached to the note with plan and documentation of communication |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Comments | Current smoking status always asked with advisement to quit, facility is currently revamping Tobacco Cessation program with plans for referral once re-established. |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Comments | Radiology service is very active in lung cancer screening and now incidental nodules; utilize low dose CT scans dedicated to incidental nodules (outside of LCS designation), with high dose CT scans utilized for Ion Robotic bronchoscopy planning |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Comments | Tracking is currently performed within VA CCTS program. Looking into purchasing Optellum in the future for tracking |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Comments | QI performed on a monthly basis with direct reporting to facility chief of staff on a quarterly basis |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Comments | All incidental nodules on various types of imaging studies are flagged by radiology and automatically detected by our Clinical Surveillance Unit (CSU) Incidental Nodule coordinator. Primary care, specialiteis and inpatient teams can also refer for consultation/tracking directly to CSU coordinator |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Comments | Utilizing "flagging codes" by Radiology |
| Name | Alison Larson |
| Title | CSU Incidental Nodule coordinator |
| Alison.Larson1@va.gov | |
| Phone | (505)-265-1711 |
| User ID | Arjan Flora |
| Facility ID | 2019 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Joel Helmke |
| Title | CEO, Knight Cancer Institute |
| lungcancer@ohsu.edu | |
| Phone | (503)-494-8311 |
| User ID | Chara Rydzak |
| Facility ID | 1957 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Joel Helmke |
| Title | CEO, Knight Cancer Institute |
| lungcancer@ohsu.edu | |
| Phone | (503)-494-8311 |
| User ID | Chara Rydzak |
| Facility ID | 1957 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Comments | We offer a peer reviewed internal cessation program available to all patients and employees. This started as a Moonshot grant funded program. |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jennifer Teeples |
| Title | Director of Clinical Business Planning and Cancer Registry |
| teeples@ohsu.edu | |
| Phone | (503)-453-7578 |
| User ID | Chara Rydzak |
| Facility ID | 1957 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Comments | We have a partnership with an outside facility to refer for surgical intervention if needed. |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | No |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | No |
| Name | Katelyn Grados |
| Title | Lung Screening Program Coordinator |
| kmg0322@mountnittany.org | |
| Phone | (814)-231-6881 |
| User ID | Katelyn Grados |
| Facility ID | 1559 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Michael Mair |
| Title | RN |
| michael.mair@commonspirit.org | |
| Phone | (916)-962-8864 |
| User ID | Michael Mair |
| Facility ID | 2178 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Michael Mair |
| Title | RN |
| michael.mair@commonspirit.org | |
| Phone | (916)-962-8864 |
| User ID | Michael Mair |
| Facility ID | 2177 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Michael Mair |
| Title | RN |
| michael.mair@commonspirit.org | |
| Phone | (916)-962-8864 |
| User ID | Michael Mair |
| Facility ID | 2176 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Michael Mair |
| Title | RN |
| michael.mair@commonspirit.org | |
| Phone | (916)-962-8864 |
| User ID | Michael Mair |
| Facility ID | 2175 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Michael Mair |
| Title | RN |
| michael.mair@commonspirit.org | |
| Phone | (916)-962-8864 |
| User ID | Michael Mair |
| Facility ID | 2174 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | No |
| Comments | Incidental only come from AI dashboard. |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Melissa Jane Clark |
| Title | RN Lung Program Coordinator |
| melissa.jane.clark@adventhealth.com | |
| Phone | (863)-386-6475 |
| User ID | melissa Clark |
| Facility ID | 1912 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sydney |
| Title | CT LUNG NAVIGATOR |
| gilmansm2@upmc.edu | |
| Phone | (724)-250-4594 |
| User ID | SYDNEY GILMAN |
| Facility ID | 1766 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sydney |
| Title | CT LUNG NAVIGATOR |
| gilmansm2@upmc.edu | |
| Phone | (724)-250-4594 |
| User ID | SYDNEY GILMAN |
| Facility ID | 1775 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sydney |
| Title | CT LUNG NAVIGATOR |
| gilmansm2@upmc.edu | |
| Phone | (724)-250-4594 |
| User ID | SYDNEY GILMAN |
| Facility ID | 1765 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Kori Pitt |
| Title | Oncology Program Manager |
| kori.pitt@renown.org | |
| Phone | (775)-982-6035 |
| User ID | Kori Pitt |
| Facility ID | 1790 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Kori Pitt |
| Title | Oncology Program Manager |
| kori.pitt@renown.org | |
| Phone | (775)-982-6035 |
| User ID | Kori Pitt |
| Facility ID | 1790 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kori Pitt |
| Title | Oncology Program Manager |
| kori.pitt@renown.org | |
| Phone | (775)-982-6035 |
| User ID | Kori Pitt |
| Facility ID | 1790 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Amy Williams |
| Title | Oncology Program Leader |
| Amy.Williams13@hcahealthcare.com | |
| Phone | (941)-792-6236 |
| User ID | Amy Willams |
| Facility ID | 1881 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Comments | We have an incidental lung nodule program managed by Care Assure. |
| Name | Amy Williams |
| Title | Oncology Program Leader |
| Amy.Williams13@hcahealthcare.com | |
| Phone | (941)-792-6236 |
| User ID | Amy Willams |
| Facility ID | 1881 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Amy Williams |
| Title | Oncology Program Leader |
| Amy.Williams13@hcahealthcare.com | |
| Phone | (941)-792-6236 |
| User ID | Amy Willams |
| Facility ID | 1881 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amy Williams |
| Title | Oncology Program Leader |
| Amy.Williams13@hcahealthcare.com | |
| Phone | (941)-792-6236 |
| User ID | Amy Willams |
| Facility ID | 1881 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Andrea Potter |
| Title | Thoracic Nurse Navigator |
| Andrea.potter@providence.org | |
| Phone | (425)-390-4658 |
| User ID | Andrea Potter |
| Facility ID | 1517 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| Comments | WE ALSO HAVE A SELF-PAY PROGRAM THAT SCREENS HIGH-RISK PATIENTS FOR $171.00 |
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Comments | We currently use the NH QuitNow line. |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Fatima Rocco |
| Title | Lung Cancer Screening Program Coordinator |
| frocco@elliot-hs.org | |
| Phone | (603)-663-1833 |
| User ID | Fatima Rocco |
| Facility ID | 1849 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| Comments | WE ALSO HAVE A SELF-PAY PROGRAM THAT SCREENS HIGH-RISK PATIENTS FOR $171.00 |
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Comments | WE CURRENTLY USE THE NH QUITNOW |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Fatima Rocco |
| Title | Lung Ca |
| frocco@elliot-hs.org | |
| Phone | (603)-663-1833 |
| User ID | Fatima Rocco |
| Facility ID | 1848 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Sandra Jennings |
| Title | Director of Oncology Support Services |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 2169 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Sandra Jennings |
| Title | Director of Oncology Support Services |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 2169 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Sandra Jennings |
| Title | Director of Oncology Support Services |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 2169 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sandra Jennings |
| Title | Director of Oncology Support Services |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 2169 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Sandra Jennings |
| Title | Director of Oncology Support Services |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 1958 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Sandra Jennings |
| Title | Director of Oncology Support Services |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 1958 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Sandra Jennings |
| Title | Director of Oncology Support Services |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 1394 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Sandra Jennings |
| Title | Director of Oncology Support Services |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 1394 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Sandra Jennings |
| Title | Director of Oncology Support Services |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 1395 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Sandra Jennings |
| Title | Director of Oncology Support Services |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 1395 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Sandra Jennings |
| Title | Director of Oncology Support Services |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 1396 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Sandra Jennings |
| Title | Director of Oncology Support |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 1396 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Sandra Jennings |
| Title | Director of Oncology Support Services |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 1397 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Comments | weekly |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Comments | Registry |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Comments | Vizio |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Comments | AI natural language tracker |
| Name | Sandra Jennings |
| Title | Director of Oncology Support Services |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 1397 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Cassie Carroll Frazier |
| Title | Nurse Practitioner |
| fraziercc@musc.edu | |
| Phone | (843)-792-2309 |
| User ID | Cassie Frazier |
| Facility ID | 1472 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Cassie Carroll Frazier |
| Title | Nurse Practitioner |
| fraziercc@musc.edu | |
| Phone | (843)-792-2309 |
| User ID | Cassie Frazier |
| Facility ID | 2157 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Cassie Carroll Frazier |
| Title | Nurse Practitioner |
| fraziercc@musc.edu | |
| Phone | (843)-792-2309 |
| User ID | Cassie Frazier |
| Facility ID | 2163 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Cassie Carroll Frazier |
| Title | Nurse Practitioner |
| fraziercc@musc.edu | |
| Phone | (843)-792-2309 |
| User ID | Cassie Frazier |
| Facility ID | 2165 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Cassie Carroll Frazier |
| Title | Nurse Practitioner |
| fraziercc@musc.edu | |
| Phone | (843)-792-2309 |
| User ID | Cassie Frazier |
| Facility ID | 2168 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Cassie Carroll Frazier |
| Title | Nurse Practitioner |
| fraziercc@musc.edu | |
| Phone | (843)-792-2309 |
| User ID | Cassie Frazier |
| Facility ID | 2160 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Cassie Carroll Frazier |
| Title | Nurse Practitioner |
| fraziercc@musc.edu | |
| Phone | (843)-792-2309 |
| User ID | Cassie Frazier |
| Facility ID | 2162 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Cassie Carroll Frazier |
| Title | Nurse Practitioner |
| fraziercc@musc.edu | |
| Phone | (843)-792-2309 |
| User ID | Cassie Frazier |
| Facility ID | 2158 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Cassie Carroll Frazier |
| Title | Nurse Practitioner |
| fraziercc@musc.edu | |
| Phone | (843)-792-2309 |
| User ID | Cassie Frazier |
| Facility ID | 2159 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Cassie Carroll Frazier |
| Title | Nurse Practitioner |
| fraziercc@musc.edu | |
| Phone | (843)-792-2309 |
| User ID | Cassie Frazier |
| Facility ID | 2161 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Cassie Carroll Frazier |
| Title | Nurse Practitioner |
| fraziercc@musc.edu | |
| Phone | (843)-792-2309 |
| User ID | Cassie Frazier |
| Facility ID | 2167 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Cassie Carroll Frazier |
| Title | Nurse Practitioner |
| fraziercc@musc.edu | |
| Phone | (843)-792-2309 |
| User ID | Cassie Frazier |
| Facility ID | 2166 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Cassie Carroll Frazier |
| Title | Nurse Practitioner |
| fraziercc@musc.edu | |
| Phone | (843)-792-2309 |
| User ID | Cassie Frazier |
| Facility ID | 2164 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Duremelle Deutou |
| Title | FNP |
| duremelle.deutou@nychhc.org | |
| Phone | (718)-579-4946 |
| User ID | Duremelle Deutou |
| Facility ID | 2155 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Laura Eatmon |
| Title | Lung Health Nurse Navigator |
| laura.eatmon@adventhealth.com | |
| Phone | (352)-690-5675 |
| User ID | Laura Eatmon |
| Facility ID | 1690 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Laura Eatmon |
| Title | Lung Health Nurse Navigator |
| laura.eatmon@adventhealth.com | |
| Phone | (352)-690-5675 |
| User ID | Laura Eatmon |
| Facility ID | 1689 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | No |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Laura Eatmon |
| Title | Lung Health Nurse Navigator |
| laura.eatmon@adventhealth.com | |
| Phone | (352)-690-5675 |
| User ID | Laura Eatmon |
| Facility ID | 1687 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Laura Eatmon |
| Title | Lung Health Nurse Navigator |
| laura.eatmon@adventhealth.com | |
| Phone | (352)-690-5675 |
| User ID | Laura Eatmon |
| Facility ID | 1687 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Laura Eatmon |
| Title | Lung Health Nurse Navigator |
| laura.eatmon@adventhealth.com | |
| Phone | (352)-690-5675 |
| User ID | Laura Eatmon |
| Facility ID | 1687 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Laura Eatmon |
| Title | Lung Health Nurse Navigator |
| laura.eatmon@adventhealth.com | |
| Phone | (352)-690-5675 |
| User ID | Laura Eatmon |
| Facility ID | 1687 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Marly Roberson |
| Title | Martin O'Neil Cancer Center Manager |
| robersm@ah.org | |
| Phone | (707)-967-5752 |
| User ID | Marcia Lynn Beauchamp |
| Facility ID | 1911 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcia Lynn Beauchamp |
| Title | clerical associate; cancer services |
| beauchml@ah.org | |
| Phone | (707)-967-5812 |
| User ID | Marcia Lynn Beauchamp |
| Facility ID | 1911 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Arpan Patel |
| Title | Associate Professor, Chief Quality Officer for Wilmot |
| Arpan_Patel@URMC.Rochester.edu | |
| Phone | (315)-525-2102 |
| User ID | Arpan Patel |
| Facility ID | 2153 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | No |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Kelly M Frontino |
| Title | Manager |
| Kelly.Frontino@stjoe.org | |
| Phone | (714)-771-8082 |
| User ID | Kelly Frontino |
| Facility ID | 1104 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kelly M Frontino |
| Title | Manager |
| Kelly.Frontino@stjoe.org | |
| Phone | (714)-771-8082 |
| User ID | Kelly Frontino |
| Facility ID | 1104 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Kelly M Frontino |
| Title | Manager |
| Kelly.Frontino@stjoe.org | |
| Phone | (714)-771-8082 |
| User ID | Kelly Frontino |
| Facility ID | 1104 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Kerns |
| Title | Nurse Navigator |
| jessica.kerns@stelizabeth.com | |
| Phone | (859)-301-4072 |
| User ID | Jessica Kerns |
| Facility ID | 1313 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Deborah Jeskey |
| Title | Lung/GU Oncology Program Coordinator |
| Deborah.jeskey@northside.com | |
| Phone | (678)-313-1230 |
| User ID | Deb Jeskey |
| Facility ID | 1925 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Deborah Jeskey |
| Title | Lung/GU Oncology Program Coordinator |
| Deborah.jeskey@northside.com | |
| Phone | (678)-313-1230 |
| User ID | Deb Jeskey |
| Facility ID | 1924 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Deborah Jeskey |
| Title | Lung/GU Oncology Program Coordinator |
| Deborah.jeskey@northside.com | |
| Phone | (678)-313-1230 |
| User ID | Deb Jeskey |
| Facility ID | 1923 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Deb Jeskey |
| Title | Lung /GU Oncology Program Coordinator |
| Deborah.jeskey@northside.com | |
| Phone | (678)-313-1230 |
| User ID | Deb Jeskey |
| Facility ID | 1926 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | No |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Sandra Murray |
| Title | Nurse Navigator |
| sandra.murray@jefferson.edu | |
| Phone | (856)-557-5322 |
| User ID | Sandy Murray |
| Facility ID | 2152 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Sandra Murray |
| Title | Nurse Navigator |
| Sandra.murray@jefferson.edu | |
| Phone | (856)-557-5322 |
| User ID | Sandy Murray |
| Facility ID | 2152 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Sandra Murray |
| Title | Nurse Navigator |
| sandra.murray@jefferson.edu | |
| Phone | (856)-557-5322 |
| User ID | Sandy Murray |
| Facility ID | 2152 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sandra Murray |
| Title | Nurse Navigator |
| sandra.murray@jefferson.edu | |
| Phone | (856)-557-5322 |
| User ID | Sandy Murray |
| Facility ID | 2152 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | No |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Sandra Murray |
| Title | Nurse Navigator |
| sandra.murray@jefferson.edu | |
| Phone | (856)-557-5322 |
| User ID | Sandy Murray |
| Facility ID | 2151 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Sandra Murray |
| Title | Nurse Navigator |
| Sandra.murray@jefferson.edu | |
| Phone | (856)-557-5322 |
| User ID | Sandy Murray |
| Facility ID | 2151 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Sandra Murray |
| Title | Nurse Navigator |
| sandra.murray@jefferson.edu | |
| Phone | (856)-557-5322 |
| User ID | Sandy Murray |
| Facility ID | 2151 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sandra Murray |
| Title | Nurse Navigator |
| sandra.murray@jefferson.edu | |
| Phone | (856)-557-5322 |
| User ID | Sandy Murray |
| Facility ID | 2151 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | No |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Sandra Murray |
| Title | Nurse Navigator |
| sandra.murray@jefferson.edu | |
| Phone | (856)-557-5322 |
| User ID | Sandy Murray |
| Facility ID | 1322 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Sandra Murray |
| Title | Nurse Navigator |
| Sandra.murray@jefferson.edu | |
| Phone | (856)-557-5322 |
| User ID | Sandy Murray |
| Facility ID | 1322 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Sandra Murray |
| Title | Nurse Navigator |
| sandra.murray@jefferson.edu | |
| Phone | (856)-557-5322 |
| User ID | Sandy Murray |
| Facility ID | 1322 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sandra Murray |
| Title | Nurse Navigator |
| sandra.murray@jefferson.edu | |
| Phone | (856)-557-5322 |
| User ID | Sandy Murray |
| Facility ID | 1322 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | No |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Sandra Murray |
| Title | Nurse Navigator |
| sandra.murray@jefferson.edu | |
| Phone | (856)-557-5322 |
| User ID | Sandy Murray |
| Facility ID | 1323 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Sandra Murray |
| Title | Nurse Navigator |
| Sandra.murray@jefferson.edu | |
| Phone | (856)-557-5322 |
| User ID | Sandy Murray |
| Facility ID | 1323 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Sandra Murray |
| Title | Nurse Navigator |
| sandra.murray@jefferson.edu | |
| Phone | (856)-557-5322 |
| User ID | Sandy Murray |
| Facility ID | 1323 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sandra Murray |
| Title | Nurse Navigator |
| sandra.murray@jefferson.edu | |
| Phone | (856)-557-5322 |
| User ID | Sandy Murray |
| Facility ID | 1323 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | No |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Sandra Murray |
| Title | Nurse Navigator |
| sandra.murray@jefferson.edu | |
| Phone | (856)-557-5322 |
| User ID | Sandy Murray |
| Facility ID | 1324 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Sandra Murray |
| Title | Nurse Navigator |
| Sandra.murray@jefferson.edu | |
| Phone | (856)-557-5322 |
| User ID | Sandy Murray |
| Facility ID | 1324 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Sandra Murray |
| Title | Nurse Navigator |
| sandra.murray@jefferson.edu | |
| Phone | (856)-557-5322 |
| User ID | Sandy Murray |
| Facility ID | 1324 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sandra Murray |
| Title | Nurse Navigator |
| sandra.murray@jefferson.edu | |
| Phone | (856)-557-5322 |
| User ID | Sandy Murray |
| Facility ID | 1324 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Crystal Terry |
| Title | Lung Clinic Manager |
| crystal.terry@advocatehealth.org | |
| Phone | (706)-509-5021 |
| User ID | Lisa Acree |
| Facility ID | 2150 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amanda Pepple |
| Title | Director |
| amanda.pepple@trinity-health.org | |
| Phone | (734)-748-3220 |
| User ID | Amanda Pepple |
| Facility ID | 1242 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amanda Pepple |
| Title | Director |
| amanda.pepple@trinity-health.org | |
| Phone | (734)-748-3220 |
| User ID | Amanda Pepple |
| Facility ID | 1474 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Lamb |
| Title | Lung Cancer Screening Navigator |
| jessica.lamb@prismahealth.org | |
| Phone | (864)-454-4269 |
| User ID | Jessica Lamb |
| Facility ID | 2149 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Lamb |
| Title | Lung Cancer Screening Navigator |
| jessica.lamb@prismahealth.org | |
| Phone | (864)-454-4269 |
| User ID | Jessica Lamb |
| Facility ID | 2148 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Lamb |
| Title | Lung Cancer Screening Navigator |
| jessica.lamb@prismahealth.org | |
| Phone | (864)-454-4269 |
| User ID | Jessica Lamb |
| Facility ID | 2147 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Lamb |
| Title | Lung Cancer Screening Navigator |
| jessica.lamb@prismahealth.org | |
| Phone | (864)-454-4269 |
| User ID | Jessica Lamb |
| Facility ID | 2146 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Lamb |
| Title | Lung Cancer Screening Navigator |
| jessica.lamb@prismahealth.org | |
| Phone | (864)-454-4269 |
| User ID | Jessica Lamb |
| Facility ID | 2145 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Lamb |
| Title | Lung Cancer Screening Navigator |
| jessica.lamb@prismahealth.org | |
| Phone | (864)-454-4269 |
| User ID | Jessica Lamb |
| Facility ID | 2144 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Lamb |
| Title | Lung Cancer Screening Navigator |
| jessica.lamb@prismahealth.org | |
| Phone | (864)-454-4269 |
| User ID | Jessica Lamb |
| Facility ID | 2143 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Lamb |
| Title | Lung Cancer Screening Navigator |
| jessica.lamb@prismahealth.org | |
| Phone | (864)-454-4269 |
| User ID | Jessica Lamb |
| Facility ID | 2142 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Lamb |
| Title | Lung Cancer Screening Navigator |
| jessica.lamb@prismahealth.org | |
| Phone | (864)-454-4269 |
| User ID | Jessica Lamb |
| Facility ID | 2141 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Lamb |
| Title | Lung Cancer Screening Navigator |
| jessica.lamb@prismahealth.org | |
| Phone | (864)-454-4269 |
| User ID | Jessica Lamb |
| Facility ID | 1327 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Lamb |
| Title | Lung Cancer Screening Navigator |
| jessica.lamb@prismahealth.org | |
| Phone | (864)-454-4269 |
| User ID | Jessica Lamb |
| Facility ID | 2140 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Lamb |
| Title | Lung Cancer Screening Navigator |
| jessica.lamb@prismahealth.org | |
| Phone | (864)-454-4269 |
| User ID | Jessica Lamb |
| Facility ID | 2139 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Lamb |
| Title | Lung Cancer Screening Navigator |
| jessica.lamb@prismahealth.org | |
| Phone | (864)-454-4269 |
| User ID | Jessica Lamb |
| Facility ID | 2138 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Lamb |
| Title | Lung Cancer Screening Navigator |
| jessica.lamb@prismahealth.org | |
| Phone | (864)-454-4269 |
| User ID | Jessica Lamb |
| Facility ID | 2137 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Lamb |
| Title | Lung Cancer Screening Navigator |
| jessica.lamb@prismahealth.org | |
| Phone | (864)-454-4269 |
| User ID | Jessica Lamb |
| Facility ID | 2136 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Lamb |
| Title | Lung Cancer Screening Navigator |
| jessica.lamb@prismahealth.org | |
| Phone | (864)-454-4269 |
| User ID | Jessica Lamb |
| Facility ID | 1326 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Jessica Poetzsch |
| Title | Quality and Accreditation Manager |
| jessica.poetzsch@midhosp.org | |
| Phone | (860)-358-2066 |
| User ID | Jessica Poetzsch |
| Facility ID | 1041 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Wendy Daniel Firestone, BSN, RN, OCN |
| Title | Nurse Navigator |
| wendy.firestone@erlanger.org | |
| Phone | (423)-778-7460 |
| User ID | Wendy Firestone |
| Facility ID | 1914 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Wendy Daniel Firestone, BSN, RN, OCN |
| Title | Nurse Navigator |
| wendy.firestone@erlanger.org | |
| Phone | (423)-778-7460 |
| User ID | Wendy Firestone |
| Facility ID | 1914 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | David Tom Cooke, MD, FACS, MAMSE |
| Title | Physician in Chief, UC Davis Comprehensive Cancer Center |
| dtcooke@health.ucdavis.edu | |
| Phone | (916)-734-3861 |
| User ID | David Cooke |
| Facility ID | 1170 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | David Tom Cooke, MD, FACS, MAMSE |
| Title | Physician in Chief, UC Davis Comprehensive Cancer Center |
| dtcooke@health.ucdavis.edu | |
| Phone | (916)-734-3861 |
| User ID | David Cooke |
| Facility ID | 1170 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | David Tom Cooke, MD, FACS, MAMSE |
| Title | Physician in Chief, UC Davis Comprehensive Cancer Center |
| dtcooke@health.ucdavis.edu | |
| Phone | (916)-734-3861 |
| User ID | David Cooke |
| Facility ID | 1170 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | David Tom Cooke, MD, FACS, MAMSE |
| Title | Physician in Chief, UC Davis Comprehensive Cancer Center |
| dtcooke@health.ucdavis.edu | |
| Phone | (916)-734-3861 |
| User ID | David Cooke |
| Facility ID | 1170 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Denise Phelps |
| Title | RN Navigator |
| denise.phelps@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 1371 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Denise Phelps |
| Title | RN Navigator |
| denise.phelps@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 1370 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Denise Phelps |
| Title | RN Navigator |
| denise.phelps@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 2038 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Denise Phelps |
| Title | RN Navigator |
| denise.phelps@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 2030 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Denise Phelps |
| Title | RN Navigator |
| denise.phelps@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 1369 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Denise Phelps |
| Title | RN Navigator |
| denise.phelps@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 1713 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Debra Knight |
| Title | BSN, RN |
| dknight@phoebehealth.com | |
| Phone | (229)-312-5757 |
| User ID | Debra Knight |
| Facility ID | 1492 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Debra Knight |
| Title | BSN, RN, Lung Navigator |
| dknight@phoebehealth.com | |
| Phone | (229)-312-5757 |
| User ID | Debra Knight |
| Facility ID | 1198 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Lenia Batas |
| Title | Cancer Screening Program manager |
| lbatas@maimo.org | |
| Phone | (929)-627-0274 |
| User ID | Lenia Batas |
| Facility ID | 1100 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Dr. Vishal Vashistha |
| Title | Medical Director |
| VVashistha@maimo.org | |
| Phone | (718)-765-2682 |
| User ID | Lenia Batas |
| Facility ID | 1100 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 2130 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 2118 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 2126 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 2124 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 2125 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 2132 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 2131 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 2133 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Meghann Roberts |
| Title | Director of imaging |
| mroberts@windsongwny.com | |
| Phone | (716)-276-0376 |
| User ID | Meghann Roberts |
| Facility ID | 1343 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Rachael Schmidt |
| Title | Program Director |
| raschmidt@nebraskamed.com | |
| Phone | (402)-559-1889 |
| User ID | Rachael Schmidt |
| Facility ID | 2129 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Dr. Cynthia Chin |
| Title | Thoracic Surgeon |
| creilly@wphospital.org | |
| Phone | (914)-849-7299 |
| User ID | Catherine Reilly |
| Facility ID | 1063 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Brooke Ruane |
| Title | Nurse Practitioner |
| brooke.ruane@jefferson.edu | |
| Phone | (215)-503-0198 |
| User ID | Brooke Ruane |
| Facility ID | 1594 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Brooke Ruane |
| Title | Nurse Practitioner |
| brooke.ruane@jefferson.edu | |
| Phone | (215)-503-0198 |
| User ID | Brooke Ruane |
| Facility ID | 1594 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brooke Ruane |
| Title | Nurse Practitioner |
| brooke.ruane@jefferson.edu | |
| Phone | (215)-503-0198 |
| User ID | Brooke Ruane |
| Facility ID | 1594 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Brooke Ruane |
| Title | Nurse Practitioner |
| brooke.ruane@jefferson.edu | |
| Phone | (215)-503-0198 |
| User ID | Brooke Ruane |
| Facility ID | 1594 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Samantha D'Annunzio |
| Title | MD |
| sdannunzio@westmedgroup.com | |
| Phone | (914)-848-8888 |
| User ID | Elizabeth Albanese |
| Facility ID | 1866 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amy Ittersagen |
| Title | Nurse Navigator |
| Anorwich@Silvercross.org | |
| Phone | (815)-300-5853 |
| User ID | Amy Ittersagen |
| Facility ID | 2127 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Claudia Henschke |
| Title | Professor of Radiology |
| Claudia.Henschke@mountsinai.org | |
| Phone | (212)-241-2768 |
| User ID | Patricia Costello |
| Facility ID | 1113 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amanda Pepple |
| Title | Director |
| amanda.pepple@trinity-health.org | |
| Phone | (734)-748-3220 |
| User ID | Amanda Pepple |
| Facility ID | 1475 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amanda Pepple |
| Title | Director |
| amanda.pepple@trinity-health.org | |
| Phone | (734)-748-3220 |
| User ID | Amanda Pepple |
| Facility ID | 1477 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amanda Pepple |
| Title | Director |
| amanda.pepple@trinity-health.org | |
| Phone | (734)-748-3220 |
| User ID | Amanda Pepple |
| Facility ID | 1225 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 2123 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | No |
| Comments | Currently working on a process to allow Emergency and Inpatient physicians the ability to refer to nodule clinic prior to patient discharge. Referrals currently come from the patients PCP. |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Comments | The use of AI identifies all incidental nodules and sends them to navigator to manage. |
| Name | Amber Perez |
| Title | Supervisor Respiratory Therapy, Lung Disease Navigator |
| amber.perez@imail.org | |
| Phone | (303)-265-2939 |
| User ID | Amber Perez |
| Facility ID | 1319 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Mary S. McMullen |
| Title | Nurse Practitioner |
| mary.mcmullen@jefferson.edu | |
| Phone | (215)-395-8155 |
| User ID | Marta Poznanska |
| Facility ID | 1219 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Comments | ACR |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Rikki Landers |
| Title | Manager Oncology Services |
| Rikki.Landers@imail.org | |
| Phone | (720)-301-7846 |
| User ID | Catherine Bieker |
| Facility ID | 1780 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Comments | ACR |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Shana Bolliger |
| Title | Director Oncology Services |
| Shana.Bolliger@imail.org | |
| Phone | (303)-689-6256 |
| User ID | Catherine Bieker |
| Facility ID | 1783 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Comments | ACR |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Autumn Clark |
| Title | Director Oncology Services |
| Autumn.Clark@imail.org | |
| Phone | (970)-298-2464 |
| User ID | Catherine Bieker |
| Facility ID | 1782 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Autumn Clark |
| Title | Director Oncology Services |
| Autumn.Clark@imail.org | |
| Phone | (970)-298-2464 |
| User ID | Catherine Bieker |
| Facility ID | 1782 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 2122 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 2121 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 2120 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Megan Gibson |
| Title | Lung Cancer Screening Navigator |
| megan.gibson@bjc.org | |
| Phone | (314)-203-5552 |
| User ID | Megan Gibson |
| Facility ID | 1563 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Comments | we have a weekly Pulmonary Nodule clinic that we all meet to discuss these findings and next steps |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Comments | we have an encounter for md's to refer to the nodule clinic and we enter notes in their charts with our recommendations and md is aware of next steps |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Comments | the ordering MD"s are the ones required to discuss with patient's prior to ordering , but when they see a specialists they do discuss importance of cessation |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Comments | we have an actionable findings category and radiologist will send to clinic when they see it on imaging |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Joan Macallister |
| Title | Oncology Nurse Navigator |
| jmmacallister@capecodhealth.org | |
| Phone | (508)-862-7661 |
| User ID | Christine Gould |
| Facility ID | 1748 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| Comments | we review the orders before scheduling for their eligibility requirements to make sure they meet them |
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Comments | ordering providers sign an order that states by signing this order you are confirming patient has received shared decision making and importance of cessation and continuing in the program |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Comments | we use the lung rads scoring system. Fleischner's Guidelines |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Comments | we have a meeting weekly with the program coordinator, radiologist, Oncology nurse navigator, Thoracic surgeon and interventional pulmonologist |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Comments | we have created a visit type of Pulmonary nodule clinic review and once we discuss and come up with a recommendation it gets noted in the chart as an encounter and MD is notified of the plan and/or if additional testing or referrals are needed |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Comments | our EMR has system for tracking unresolved follow ups, patients are sent a reminder letter at 30 days, 60 days and 90 days overdue, after 90 notice is sent to pcp. |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Comments | we upload daily to the ACR |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Christine Gould |
| Title | Lung Cancer Screening Program Coordinator |
| cgould@capecodhealth.org | |
| Phone | (508)-862-5116 |
| User ID | Christine Gould |
| Facility ID | 2119 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| Comments | we review the orders before scheduling for their eligibility requirements to make sure they meet them |
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Comments | ordering providers sign an order that states by signing this order you are confirming patient has received shared decision making and importance of cessation and continuing in the program |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Comments | we use the lung rads scoring system. Fleischner's Guidelines |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Comments | we have a meeting weekly with the program coordinator, radiologist, Oncology nurse navigator, Thoracic surgeon and interventional pulmonologist |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Comments | we have created a visit type of Pulmonary nodule clinic review and once we discuss and come up with a recommendation it gets noted in the chart as an encounter and MD is notified of the plan and/or if additional testing or referrals are needed |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Comments | our EMR has system for tracking unresolved follow ups, patients are sent a reminder letter at 30 days, 60 days and 90 days overdue, after 90 notice is sent to pcp. |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Comments | we upload daily to the ACR |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Christine Gould |
| Title | Lung Cancer Screening Program Coordinator |
| cgould@capecodhealth.org | |
| Phone | (508)-862-5116 |
| User ID | Christine Gould |
| Facility ID | 1748 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Connie Buckley |
| Title | RN, Lung Screening Navigator |
| connie.buckley@nortonhealthcare.org | |
| Phone | (502)-636-8327 |
| User ID | Jenny Frantz |
| Facility ID | 1592 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Connie Buckley |
| Title | RN, Lung Screening Navigator |
| connie.buckley@nortonhealthcare.org | |
| Phone | (502)-636-8327 |
| User ID | Jenny Frantz |
| Facility ID | 1951 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Connie Buckley |
| Title | RN, Lung Screening Navigator |
| connie.buckley@nortonhealthcare.org | |
| Phone | (502)-636-8327 |
| User ID | Jenny Frantz |
| Facility ID | 1950 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Connie Buckley |
| Title | RN, Lung Screening Navigator |
| connie.buckley@nortonhealthcare.org | |
| Phone | (502)-636-8327 |
| User ID | Jenny Frantz |
| Facility ID | 1590 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Connie Buckley |
| Title | RN, Lung Screening Navigator |
| connie.buckley@nortonhealthcare.org | |
| Phone | (502)-636-8327 |
| User ID | Jenny Frantz |
| Facility ID | 1589 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Connie Buckley |
| Title | RN, Lung Screening Navigator |
| connie.buckley@nortonhealthcare.org | |
| Phone | (502)-636-8327 |
| User ID | Jenny Frantz |
| Facility ID | 1588 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Connie Buckley |
| Title | RN, Lung Screening Navigator |
| connie.buckley@nortonhealthcare.org | |
| Phone | (502)-636-8327 |
| User ID | Jenny Frantz |
| Facility ID | 1153 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Connie Buckley |
| Title | RN, Lung Screening Navigator |
| connie.buckley@nortonhealthcare.org | |
| Phone | (502)-636-8327 |
| User ID | Jenny Frantz |
| Facility ID | 1593 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Connie Buckley |
| Title | RN, Lung Screening Navigator |
| connie.buckley@nortonhealthcare.org | |
| Phone | (502)-636-8327 |
| User ID | Jenny Frantz |
| Facility ID | 1054 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Connie Buckley |
| Title | RN, Lung Screening Navigator |
| connie.buckley@nortonhealthcare.org | |
| Phone | (502)-636-8327 |
| User ID | Jenny Frantz |
| Facility ID | 1054 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Theresa Maciejewski |
| Title | Lead RN Patient Navigator |
| tmmaciejewski@mercy.com | |
| Phone | (513)-624-4500 |
| User ID | Theresa Maciejewski |
| Facility ID | 1306 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Theresa Maciejewski |
| Title | Lead RN Patient Navigator Mercy Health |
| tmmaciejewski@mercy.com | |
| Phone | (513)-624-4500 |
| User ID | Theresa Maciejewski |
| Facility ID | 1307 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Theresa Maciejewsi |
| Title | Lead RN Patient Navigator Mercy Health |
| tmmaciejewski@mercy.com | |
| Phone | (513)-624-4500 |
| User ID | Theresa Maciejewski |
| Facility ID | 1697 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Ellen Brennan |
| Title | Lung cancer screening Nurse Navigator |
| ellen.brennan@bjc.org | |
| Phone | (636)-916-7098 |
| User ID | Ellen Brennan |
| Facility ID | 1562 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jennifer Finch |
| Title | VP of Supply Chain |
| fincjl@mchealth.net | |
| Phone | (270)-745-1224 |
| User ID | Jennifer Finch |
| Facility ID | 2053 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jennifer Finch |
| Title | VP of Supply Chain |
| fincjl@mchealth.net | |
| Phone | (270)-745-1224 |
| User ID | Jennifer Finch |
| Facility ID | 2058 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jennifer Finch |
| Title | VP of Supply Chain |
| fincjl@mchealth.net | |
| Phone | (270)-745-1224 |
| User ID | Jennifer Finch |
| Facility ID | 2059 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jennifer Finch |
| Title | VP of Supply Chain |
| fincjl@mchealth.net | |
| Phone | (270)-745-1224 |
| User ID | Jennifer Finch |
| Facility ID | 2056 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jennifer Finch |
| Title | VP of Supply Chain |
| fincjl@mchealth.net | |
| Phone | (270)-745-1224 |
| User ID | Jennifer Finch |
| Facility ID | 2057 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jennifer Finch |
| Title | VP of Supply Chain |
| fincjl@mchealth.net | |
| Phone | (270)-745-1224 |
| User ID | Jennifer Finch |
| Facility ID | 2055 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Jessica Kerns |
| Title | Nurse Navigator |
| jessica.kerns@stelizabeth.com | |
| Phone | (859)-301-4072 |
| User ID | Jessica Kerns |
| Facility ID | 1313 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Jessica Kerns |
| Title | Nurse Navigator |
| jessica.kerns@stelizabeth.com | |
| Phone | (859)-301-4072 |
| User ID | Jessica Kerns |
| Facility ID | 1312 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Jessica Kerns |
| Title | Nurse Navigator |
| jessica.kerns@stelizabeth.com | |
| Phone | (859)-301-4072 |
| User ID | Jessica Kerns |
| Facility ID | 1311 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Jessica Kerns |
| Title | Nurse Navigator |
| jessica.kerns@stelizabeth.com | |
| Phone | (859)-301-4072 |
| User ID | Jessica Kerns |
| Facility ID | 1310 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Jessica Kerns |
| Title | Nurse Navigator |
| jessica.kerns@stelizabeth.com | |
| Phone | (859)-301-4072 |
| User ID | Jessica Kerns |
| Facility ID | 1309 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Jessica Kerns |
| Title | Nurse Navigator |
| jessica.kerns@stelizabeth.com | |
| Phone | (859)-301-4072 |
| User ID | Jessica Kerns |
| Facility ID | 1308 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Kerns |
| Title | Nurse Navigator |
| jessica.kerns@stelizabeth.com | |
| Phone | (859)-301-4072 |
| User ID | Jessica Kerns |
| Facility ID | 1312 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Kerns |
| Title | Nurse Navigator |
| jessica.kerns@stelizabeth.com | |
| Phone | (859)-301-4072 |
| User ID | Jessica Kerns |
| Facility ID | 1311 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Kerns |
| Title | Nurse Navigator |
| jessica.kerns@stelizabeth.com | |
| Phone | (859)-301-4072 |
| User ID | Jessica Kerns |
| Facility ID | 1310 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Kerns |
| Title | Nurse Navigator |
| jessica.kerns@stelizabeth.com | |
| Phone | (859)-301-4072 |
| User ID | Jessica Kerns |
| Facility ID | 1309 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jessica Kerns |
| Title | Nurse Navigator |
| jessica.kerns@stelizabeth.com | |
| Phone | (859)-301-4072 |
| User ID | Jessica Kerns |
| Facility ID | 1308 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | No |
| Comments | unsure |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Denise Phelps |
| Title | RN Navigator |
| denise.phelps@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 1371 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | No |
| Comments | unsure |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Denise Phelps |
| Title | RN Navigator |
| denise.phelps@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 1370 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | No |
| Comments | unsure |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Denise Phelps |
| Title | RN Navigator |
| denise.phelps@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 2038 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | No |
| Comments | unsure |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Denise Phelps |
| Title | RN Navigator |
| denise.phelps@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 2030 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | No |
| Comments | Unsure |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Denise Phelps |
| Title | RN Navigator |
| denise.phelps@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 1369 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 1441 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 1440 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 1439 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| Comments | we use the USPSTF criteria |
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Comments | Will be getting a commerical dashboard that will allow us to pull these reports hopefully within the year. We do not currently have this tracking capability. |
| Name | Denise Phelps |
| Title | RN Navigator |
| denise.phelps@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 2033 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 1438 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Lauren Carbo |
| Title | Project Manager, Lung Cancer Screening |
| rsd6wu@uvahealth.org | |
| Phone | (410)-533-4590 |
| User ID | Lauren Carbo |
| Facility ID | 2115 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Lauren Carbo |
| Title | Project Manager, Lung Cancer Screening |
| rsd6wu@uvahealth.org | |
| Phone | (410)-533-4590 |
| User ID | Lauren Carbo |
| Facility ID | 2117 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Lauren Carbo |
| Title | Project Manager, Lung Cancer Screening |
| rsd6wu@uvahealth.org | |
| Phone | (410)-533-4590 |
| User ID | Lauren Carbo |
| Facility ID | 2116 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Lauren Carbo |
| Title | Project Manager, Lung Cancer Screening |
| rsd6wu@uvahealth.org | |
| Phone | (410)-533-4590 |
| User ID | Lauren Carbo |
| Facility ID | 1213 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Lauren Carbo |
| Title | Project Manager, Lung Cancer Screening |
| rsd6wu@uvahealth.org | |
| Phone | (410)-533-4590 |
| User ID | Lauren Carbo |
| Facility ID | 1568 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Lauren Carbo |
| Title | Project Manager, Lung Cancer Screening |
| rsd6wu@uvahealth.org | |
| Phone | (410)-533-4590 |
| User ID | Lauren Carbo |
| Facility ID | 1212 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Lauren Carbo |
| Title | Project Manager, Lung Cancer Screening |
| rsd6wu@uvahealth.org | |
| Phone | (410)-533-4590 |
| User ID | Lauren Carbo |
| Facility ID | 1211 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Craig Barr |
| Title | Executive Director |
| cbarr@hvhs.org | |
| Phone | (724)-773-4578 |
| User ID | Kathleen Osten |
| Facility ID | 1270 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Craig Barr |
| Title | Executive Director |
| cbarr@hvhs.org | |
| Phone | (724)-773-4578 |
| User ID | Kathleen Osten |
| Facility ID | 1269 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 1437 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 1436 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 1434 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 1433 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Comments | We track positive LCS patients. |
| Name | Lisa Fowlkes |
| Title | Lung Cancer Screening Coordinator RN |
| Lisa.Fowlkes@vcuhealth.org | |
| Phone | (804)-627-7939 |
| User ID | Lisa Fowlkes |
| Facility ID | 2114 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Comments | We track positive LCS patients. |
| Name | Lisa Fowlkes |
| Title | Lung Cancer Screening Coordinator RN |
| Lisa.Fowlkes@vcuhealth.org | |
| Phone | (804)-628-7939 |
| User ID | Lisa Fowlkes |
| Facility ID | 2110 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Comments | We track positive LCS patients. |
| Name | Lisa Fowlkes |
| Title | Lung Cancer Screening Coordinator |
| Lisa.Fowlkes@vcuhealth.org | |
| Phone | (804)-627-7939 |
| User ID | Lisa Fowlkes |
| Facility ID | 2111 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Comments | We track positive LCS patients. |
| Name | Lisa Fowlkes |
| Title | Lung Cancer Screening Coordinator RN |
| Lisa.Fowlkes@vcuhealth.org | |
| Phone | (804)-628-7939 |
| User ID | Lisa Fowlkes |
| Facility ID | 2113 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Comments | We track positive LCS patients. |
| Name | Lisa Fowlkes |
| Title | Lung Cancer Screening Coordinator RN |
| Lisa.Fowlkes@vcuhealth.org | |
| Phone | (804)-628-7939 |
| User ID | Lisa Fowlkes |
| Facility ID | 2112 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 1435 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Elizabeth Campana |
| Title | Program Manager/ Patient Navigator |
| elizabeth.s.campana@lahey.org | |
| Phone | (781)-744-7192 |
| User ID | Elizabeth Campana |
| Facility ID | 1075 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Comments | We track positive LCS patients. |
| Name | Lisa Fowlkes |
| Title | Lung Cancer Screening Coordinator RN |
| LIsa.fowlkes@vcuhealth.org | |
| Phone | (804)-628-7939 |
| User ID | Lisa Fowlkes |
| Facility ID | 1060 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kendal Delaney |
| Title | BSN, RN Oncology Nurse Navigator |
| Kendal_Delaney@Mercy.com | |
| Phone | (419)-265-9715 |
| User ID | Kendal Delaney |
| Facility ID | 1391 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kendal Delaney |
| Title | BSN, RN Oncology Nurse Navigator |
| Kendal_Delaney@Mercy.com | |
| Phone | (419)-265-9715 |
| User ID | Kendal Delaney |
| Facility ID | 1390 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kendal Delaney |
| Title | BSN, RN Oncology Nurse Navigator |
| Kendal_Delaney@Mercy.com | |
| Phone | (419)-265-9715 |
| User ID | Kendal Delaney |
| Facility ID | 1389 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kendal Delaney |
| Title | BSN, RN Oncology Nurse Navigator |
| Kendal_Delaney@Mercy.com | |
| Phone | (419)-265-9715 |
| User ID | Kendal Delaney |
| Facility ID | 1388 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kendal Delaney |
| Title | BSN, RN Oncology Nurse Navigator |
| Kendal_Delaney@Mercy.com | |
| Phone | (419)-265-9715 |
| User ID | Kendal Delaney |
| Facility ID | 1387 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kendal Delaney |
| Title | BSN, RN Oncology Navigator |
| Kendal_Delaney@Mercy.com | |
| Phone | (419)-265-9715 |
| User ID | Kendal Delaney |
| Facility ID | 1386 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kendal Delaney |
| Title | BSN, RN Oncology Navigator |
| Kendal_Delaney@Mercy.com | |
| Phone | (419)-265-9715 |
| User ID | Kendal Delaney |
| Facility ID | 1385 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jean M Comeau BSN RN |
| Title | Nurse Navigator |
| jean.comeau@umassmemorial.org | |
| Phone | (508)-765-3024 |
| User ID | Jean Comeau |
| Facility ID | 2108 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kendra Worden |
| Title | NP |
| kworden@mhc.net | |
| Phone | (231)-392-8486 |
| User ID | Kendra Worden |
| Facility ID | 1021 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kendra Worden |
| Title | NP |
| kworden@mhc.net | |
| Phone | (231)-392-8486 |
| User ID | Kendra Worden |
| Facility ID | 1028 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amy Hamm, RN |
| Title | Lung Nodule Program Coordinator |
| amy.hamm@hcahealthcare.com | |
| Phone | (727)-619-0436 |
| User ID | Amy Hamm |
| Facility ID | 1773 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kendra Worden |
| Title | NP |
| kworden@mhc.net | |
| Phone | (231)-392-8486 |
| User ID | Kendra Worden |
| Facility ID | 1027 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amy Hamm, RN |
| Title | Lung Nodule Program Coordinator |
| amy.hamm@hcahealthcare.com | |
| Phone | (727)-619-0436 |
| User ID | Amy Hamm |
| Facility ID | 1771 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kendra Worden |
| Title | NP |
| kworden@mhc.net | |
| Phone | (231)-392-8486 |
| User ID | Kendra Worden |
| Facility ID | 1026 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amy Hamm, RN |
| Title | Lung Nodule Program Coordinator |
| amy.hamm@hcahealthcare.com | |
| Phone | (727)-619-0436 |
| User ID | Amy Hamm |
| Facility ID | 1772 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kendra Worden |
| Title | NP |
| kworden@mhc.net | |
| Phone | (231)-392-8486 |
| User ID | Kendra Worden |
| Facility ID | 1023 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Amy Hamm |
| Title | Lung Nodule Program Coordinator |
| amy.hamm@hcahealthcare.com | |
| Phone | (727)-619-0436 |
| User ID | Amy Hamm |
| Facility ID | 1770 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kendra Worden |
| Title | NP |
| kworden@mhc.net | |
| Phone | (231)-392-8486 |
| User ID | Kendra Worden |
| Facility ID | 1024 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kendra Worden |
| Title | NP |
| kworden@mhc.net | |
| Phone | (231)-392-8486 |
| User ID | Kendra Worden |
| Facility ID | 1022 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Amy Hamm |
| Title | RN |
| amy.hamm@hcahealthcare.com | |
| Phone | (727)-619-0436 |
| User ID | Amy Hamm |
| Facility ID | 1770 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kendra Worden |
| Title | NP |
| kworden@mhc.net | |
| Phone | (231)-392-8486 |
| User ID | Kendra Worden |
| Facility ID | 1025 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Amy Hamm |
| Title | RN |
| amy.hamm@hcahealthcare.com | |
| Phone | (727)-619-0436 |
| User ID | Amy Hamm |
| Facility ID | 1770 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amy Hamm |
| Title | RN |
| amy.hamm@hcahealthcare.com | |
| Phone | (727)-619-0436 |
| User ID | Amy Hamm |
| Facility ID | 1770 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Lauren Carbo |
| Title | Project Manager, Lung Cancer Screening |
| rsd6wu@uvahealth.org | |
| Phone | (410)-533-4590 |
| User ID | Lauren Carbo |
| Facility ID | 1210 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| Comments | Patients who do not meet standard criteria but fulfill NCCN group 2 or other high risk criteria such as prolonged occupational exposures / family history etc.,. may obtain their screening via self pay following SDM with the healthcare provider. |
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marquis Demniak, APP |
| Title | LCSP Coordinator |
| Marquis.demniak@hsc.wvu.edu | |
| Phone | (304)-598-4882 |
| User ID | Melanie Moccaldi |
| Facility ID | 1112 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Joy Brown |
| Title | Radiology Quality & Compliance Coordinator |
| jbrown@limamemorial.org | |
| Phone | (419)-226-5096 |
| User ID | Joy Brown |
| Facility ID | 1220 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Susan Lessar |
| Title | Vice President, Operations and Oncology Service Line |
| slessar@valleyhealthlink.com | |
| Phone | (540)-536-1882 |
| User ID | Lindsey Temple |
| Facility ID | 1747 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Brandy Dietz |
| Title | Telehealth Nurse |
| brandy.dietz@uchealth.com | |
| Phone | (513)-584-0135 |
| User ID | Brandy Waits |
| Facility ID | 1351 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Brandy Dietz |
| Title | Telehealth Nurse |
| brandy.dietz@uchealth.com | |
| Phone | (513)-584-0135 |
| User ID | Brandy Waits |
| Facility ID | 2106 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Brandy Dietz |
| Title | Telehealth Nurse |
| brandy.dietz@uchealth.com | |
| Phone | (513)-584-0135 |
| User ID | Brandy Waits |
| Facility ID | 1066 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Brandy Dietz |
| Title | Telehealth Nurse |
| brandy.dietz@uchealth.com | |
| Phone | (513)-584-0135 |
| User ID | Brandy Waits |
| Facility ID | 2107 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Brandy Dietz |
| Title | Telehealth Nurse |
| brandy.dietz@uchealth.com | |
| Phone | (513)-584-0135 |
| User ID | Brandy Waits |
| Facility ID | 1350 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Lauren Moore |
| Title | Thoracic Oncology Program Coordinator |
| lauren.moore@tidalhealth.org | |
| Phone | (410)-543-7012 |
| User ID | Lauren Moore |
| Facility ID | 2007 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Celeste Titus |
| Title | Screening Coordinator |
| titusc@karmanos.org | |
| Phone | (248)-226-2129 |
| User ID | Celeste Titus |
| Facility ID | 1426 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | No |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Comments | nurse navigators follow treatment of patient to make sure they are receiving what recommendations state from LDCT |
| Calculated Section Total | 8 |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Comments | documented on treatment plan |
| Name | Heather Newcomb |
| Title | Clinical coordinator |
| hnewcomb@saratogahospital.org | |
| Phone | (518)-580-2855 |
| User ID | Heather Newcomb |
| Facility ID | 1574 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Brandy Dietz |
| Title | Telehealth Nurse |
| brandy.dietz@uchealth.com | |
| Phone | (513)-584-0135 |
| User ID | Brandy Waits |
| Facility ID | 1351 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Brandy Dietz |
| Title | Telehealth Nurse |
| brandy.dietz@uchealth.com | |
| Phone | (513)-584-0135 |
| User ID | Brandy Waits |
| Facility ID | 2106 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Brandy Dietz |
| Title | Telehealth Nurse |
| brandy.dietz@uchealth.com | |
| Phone | (513)-584-0135 |
| User ID | Brandy Waits |
| Facility ID | 1066 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Brandy Dietz |
| Title | Telehealth Nurse |
| brandy.dietz@uchealth.com | |
| Phone | (513)-584-0135 |
| User ID | Brandy Waits |
| Facility ID | 2107 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Brandy Dietz |
| Title | Telehealth Nurse |
| brandy.dietz@uchealth.com | |
| Phone | (513)-584-0135 |
| User ID | Brandy Waits |
| Facility ID | 1350 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Brandy Dietz |
| Title | Telehealth Nurse |
| brandy.dietz@uchealth.com | |
| Phone | (513)-584-0135 |
| User ID | Brandy Waits |
| Facility ID | 1351 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Brandy Dietz |
| Title | Telehealth Nurse |
| brandy.dietz@uchealth.com | |
| Phone | (513)-584-0135 |
| User ID | Brandy Waits |
| Facility ID | 2106 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Brandy Dietz |
| Title | Telehealth Nurse |
| brandy.dietz@uchealth.com | |
| Phone | (513)-584-0135 |
| User ID | Brandy Waits |
| Facility ID | 1066 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Brandy Dietz |
| Title | Telehealth Nurse |
| brandy.dietz@uchealth.com | |
| Phone | (513)-584-0135 |
| User ID | Brandy Waits |
| Facility ID | 2107 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Brandy Dietz |
| Title | Telehealth Nurse |
| brandy.dietz@uchealth.com | |
| Phone | (513)-584-0135 |
| User ID | Brandy Waits |
| Facility ID | 1350 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brandy Dietz |
| Title | Telehealth Nurse |
| brandy.dietz@uchealth.com | |
| Phone | (513)-584-0135 |
| User ID | Brandy Waits |
| Facility ID | 2106 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brandy Dietz |
| Title | Telehealth Nurse |
| brandy.dietz@uchealth.com | |
| Phone | (513)-584-0135 |
| User ID | Brandy Waits |
| Facility ID | 2107 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brandy Dietz |
| Title | Telehealth Nurse |
| brandy.dietz@uchealth.com | |
| Phone | (513)-584-0135 |
| User ID | Brandy Waits |
| Facility ID | 1351 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brandy Dietz |
| Title | Telehealth Nurse |
| brandy.dietz@uchealth.com | |
| Phone | (513)-584-0135 |
| User ID | Brandy Waits |
| Facility ID | 1066 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brandy Dietz |
| Title | Telehealth Nurse |
| brandy.dietz@uchealth.com | |
| Phone | (513)-584-0135 |
| User ID | Brandy Waits |
| Facility ID | 1350 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Comments | ACR LCSR |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 1105 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Comments | ACR LCSR |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brenna Offutt |
| Title | Nursing Supervisor |
| Brenna.Milankovich@ahn.org | |
| Phone | (412)-215-8509 |
| User ID | Brenna Milankovich |
| Facility ID | 1430 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jean Comeau BSN RN |
| Title | Nurse Navigator |
| jean.comeau@umassmemorial.org | |
| Phone | (508)-765-3024 |
| User ID | Jean Comeau |
| Facility ID | 1626 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Stacey Pinckney |
| Title | Nurse Navigator |
| stacey.pinckney@umhwest.org | |
| Phone | (616)-252-5220 |
| User ID | Stacey Pinckney |
| Facility ID | 1653 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Kelly Horn |
| Title | Director of Marketing and Community Outreach, Physician Liaison |
| khorn@nebraskacancer.com | |
| Phone | (531)-329-3655 |
| User ID | Kelly Horn |
| Facility ID | 2090 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | KELLY HORN |
| Title | Director of Marketing and Community Outreach, Physician Liaison |
| khorn@nebraskacancer.com | |
| Phone | (531)-329-3655 |
| User ID | Kelly Horn |
| Facility ID | 2090 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amy McClary |
| Title | RN Patient Navigator |
| amcclary@northernlight.org | |
| Phone | (207)-973-5822 |
| User ID | Amy McClary |
| Facility ID | 1874 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Stuart Cohen, MD |
| Title | Radiologist |
| SLCohen@northwell.edu | |
| Phone | (516)-562-2819 |
| User ID | Kristina Sopp |
| Facility ID | 2105 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Stuart Cohen, MD |
| Title | Radiologist |
| SLCohen@northwell.edu | |
| Phone | (516)-562-2819 |
| User ID | Kristina Sopp |
| Facility ID | 1945 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Stuart Cohen, MD |
| Title | Radiologist |
| SLCohen@northwell.edu | |
| Phone | (516)-562-2819 |
| User ID | Kristina Sopp |
| Facility ID | 1294 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Stuart Cohen, MD |
| Title | Radiologist |
| SLCohen@northwell.edu | |
| Phone | (516)-562-2819 |
| User ID | Kristina Sopp |
| Facility ID | 2027 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Stuart Cohen, MD |
| Title | Radiologist |
| SLCohen@northwell.edu | |
| Phone | (516)-562-2819 |
| User ID | Kristina Sopp |
| Facility ID | 2028 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Stuart Cohen, MD |
| Title | Radiologist |
| SLCohen@northwell.edu | |
| Phone | (516)-562-2819 |
| User ID | Kristina Sopp |
| Facility ID | 1293 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Stuart Cohen, MD |
| Title | Radiologist |
| SLCohen@northwell.edu | |
| Phone | (516)-562-2819 |
| User ID | Kristina Sopp |
| Facility ID | 2024 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Stuart Cohen, MD |
| Title | Radiologist |
| SLCohen@northwell.edu | |
| Phone | (516)-562-2819 |
| User ID | Kristina Sopp |
| Facility ID | 2025 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Stuart Cohen, MD |
| Title | Radiologist |
| SLCohen@northwell.edu | |
| Phone | (516)-562-2819 |
| User ID | Kristina Sopp |
| Facility ID | 2026 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Stuart Cohen, MD |
| Title | Radiologist |
| SLCohen@northwell.edu | |
| Phone | (516)-562-2819 |
| User ID | Kristina Sopp |
| Facility ID | 1287 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Stuart Cohen, MD |
| Title | Radiologist |
| SLCohen@northwell.edu | |
| Phone | (516)-562-2819 |
| User ID | Kristina Sopp |
| Facility ID | 1137 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Stuart Cohen, MD |
| Title | Radiologist |
| SLCohen@northwell.edu | |
| Phone | (516)-562-2819 |
| User ID | Kristina Sopp |
| Facility ID | 2023 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Stuart Cohen, MD |
| Title | Radiologist |
| SLCohen@northwell.edu | |
| Phone | (516)-562-2819 |
| User ID | Kristina Sopp |
| Facility ID | 1281 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Stuart Cohen, MD |
| Title | Radiologist |
| SLCohen@northwell.edu | |
| Phone | (516)-562-2819 |
| User ID | Kristina Sopp |
| Facility ID | 1286 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Stuart Cohen, MD |
| Title | Radiologist |
| SLCohen@northwell.edu | |
| Phone | (516)-562-2819 |
| User ID | Kristina Sopp |
| Facility ID | 1283 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amy Rodriguez |
| Title | Registered Nurse |
| amy.rodriguez2@imail.org | |
| Phone | (303)-403-3611 |
| User ID | Amy Rodriguez |
| Facility ID | 1319 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| Comments | The patients will discuss with program provider whom will identify additional risk factors including family history of lung cancer, exposures to radon/asbestos/mold etc, 2nd hand smoking exposures, and past medical history of other cancers. |
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Comments | LungRADS |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Comments | At minimum: Clinical program coordinator, Pulmonology, Interventional Pulmonology, and Thoracic Surgery. |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Comments | PenRAD / PenLUNG |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Comments | ACR LCSR |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Comments | in process of development |
| Name | Vita Balista |
| Title | FNP |
| vita.balista@wmchealth.org | |
| Phone | (914)-306-0274 |
| User ID | Vita Balista |
| Facility ID | 2104 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Emilia Arndt |
| Title | Director |
| emilia.arndt@hcahealthcare.com | |
| Phone | (352)-333-4703 |
| User ID | Emilia Arndt |
| Facility ID | 2103 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jared Ediger |
| Title | Oncology Navigator |
| david.ediger@adventhealth.com | |
| Phone | (303)-778-2415 |
| User ID | Jared Ediger |
| Facility ID | 1726 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Rikki Landers |
| Title | Manager Oncology Services |
| Rikki.Landers@imail.org | |
| Phone | (720)-301-7846 |
| User ID | Catherine Bieker |
| Facility ID | 1780 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Katie Donnelly |
| Title | Director Nursing Onc Hospice and Palliative Care |
| Katie.Donnelly@imail.org | |
| Phone | (406)-233-4029 |
| User ID | Catherine Bieker |
| Facility ID | 1789 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Katie Donnelly |
| Title | Director Nursing Onc Hospice and Palliative Care |
| Katie.Donnelly@imail.org | |
| Phone | (406)-233-4029 |
| User ID | Catherine Bieker |
| Facility ID | 1789 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Katie Donnelly |
| Title | Director Nursing Onc Hospice and Palliative Care |
| Katie.Donnelly@imail.org | |
| Phone | (406)-233-4029 |
| User ID | Catherine Bieker |
| Facility ID | 1781 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Jerri Doyle |
| Title | Director Nursing Oncology Service Line |
| Jerri.Doyle@imail.org | |
| Phone | (406)-723-2840 |
| User ID | Catherine Bieker |
| Facility ID | 1788 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Shana Bolliger |
| Title | Director Oncology Service Line |
| Shana.Bolliger@imail.org | |
| Phone | (303)-689-6256 |
| User ID | Catherine Bieker |
| Facility ID | 1783 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amy Rodriguez |
| Title | RN Navigator Oncology |
| Amy.Rodriguez2@imail.org | |
| Phone | (303)-403-3611 |
| User ID | Catherine Bieker |
| Facility ID | 1784 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Casey Bogenschutz |
| Title | Director Oncology Service Line |
| Casey.Bogenschutz@imail.org | |
| Phone | (303)-467-8845 |
| User ID | Catherine Bieker |
| Facility ID | 1784 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Sarah Pike |
| Title | Director Oncology Service Line |
| Sarah.Pike@imail.org | |
| Phone | (303)-318-3471 |
| User ID | Catherine Bieker |
| Facility ID | 1781 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Comments | CoC & NAPBC accredited |
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | No |
| Comments | CT surgeons on medical staff, but not fellowship trained in thoracic oncology |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 9 |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | No |
| Comments | No fellowship trained Thoracic Oncologist - only board certified CT surgeons |
| Name | CJ Johnson |
| Title | Administrative Director - Oncology |
| cj.johnson@hcahealthcare.com | |
| Phone | (352)-333-5917 |
| User ID | CJ Johnson |
| Facility ID | 2102 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Stephanie L Brown |
| Title | RN, BSN, Nurse Navigator |
| stephanie.brown@uchealth.org | |
| Phone | (720)-848-6495 |
| User ID | Stephanie Brown |
| Facility ID | 1399 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Stephanie L Brown |
| Title | RN, BSN, Nurse Navigator |
| stephanie.brown@uchealth.org | |
| Phone | (303)-523-1556 |
| User ID | Stephanie Brown |
| Facility ID | 1399 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Comments | done by the referring provider |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Comments | referral to the quit line if indicated |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marguerite Thomas |
| Title | cancer center program and accreditation coordinator |
| Peggy.thomas900@commonspirit.org | |
| Phone | (719)-776-8202 |
| User ID | Peggy Thomas |
| Facility ID | 1384 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Comments | this is done by the referring provider. reinforced if needed by the navigators |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Comments | this is provided by the referring provider through referral to the quit line |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marguerite Thomas |
| Title | cancer center program and accreditation coordinator |
| Peggy.thomas900@commonspirit.org | |
| Phone | (719)-776-8202 |
| User ID | Peggy Thomas |
| Facility ID | 1383 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Mary Jo Evans |
| Title | Administrator, Imaging Population Health |
| maryjo_evans@urmc.rochester.edu | |
| Phone | (585)-773-8960 |
| User ID | Mary Jo Evans |
| Facility ID | 2093 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Mary Jo Evans |
| Title | Administrator, Imaging Population Health |
| maryjo_evans@urmc.rochester.edu | |
| Phone | (585)-773-8960 |
| User ID | Mary Jo Evans |
| Facility ID | 2092 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Mary Jo Evans |
| Title | Administrator, Imaging Population Health |
| maryjo_evans@urmc.rochester.edu | |
| Phone | (585)-773-8960 |
| User ID | Mary Jo Evans |
| Facility ID | 2100 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Mary Jo Evans |
| Title | Administrator, Imaging Population Health |
| maryjo_evans@urmc.rochester.edu | |
| Phone | (585)-773-8960 |
| User ID | Mary Jo Evans |
| Facility ID | 2091 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Mary Jo Evans |
| Title | Administrator, Imaging Population Health |
| maryjo_evans@urmc.rochester.edu | |
| Phone | (585)-773-8960 |
| User ID | Mary Jo Evans |
| Facility ID | 2099 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Mary Jo Evans |
| Title | Administrator, Imaging Population Health |
| maryjo_evans@urmc.rochester.edu | |
| Phone | (585)-773-8960 |
| User ID | Mary Jo Evans |
| Facility ID | 2097 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Mary Jo Evans |
| Title | Administrator, Imaging Population Health |
| maryjo_evans@urmc.rochester.edu | |
| Phone | (585)-773-8960 |
| User ID | Mary Jo Evans |
| Facility ID | 2096 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Mary Jo Evans |
| Title | Administrator, Imaging Population Health |
| maryjo_evans@urmc.rochester.edu | |
| Phone | (585)-773-8960 |
| User ID | Mary Jo Evans |
| Facility ID | 2098 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Mary Jo Evans |
| Title | Administrator, Imaging Population Health |
| maryjo_evans@urmc.rochester.edu | |
| Phone | (585)-773-8960 |
| User ID | Mary Jo Evans |
| Facility ID | 2094 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Mary Jo Evans |
| Title | Administrator, Imaging Population Health |
| maryjo_evans@urmc.rochester.edu | |
| Phone | (585)-773-8960 |
| User ID | Mary Jo Evans |
| Facility ID | 2095 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Michelle Heron, RN |
| Title | Director of Operations |
| michelle.heron@stjoe.org | |
| Phone | (707)-525-6654 |
| User ID | Kelly Farrow |
| Facility ID | 2011 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kelly Farrow, RN |
| Title | Registered Nurse |
| kelly.farrow@stjoe.org | |
| Phone | (707)-525-6648 |
| User ID | Kelly Farrow |
| Facility ID | 2011 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | No |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Kathryn Campuzano |
| Title | Thoracic Oncology/Screening Nurse Navigator |
| KCampuzano@memorialcare.org | |
| Phone | (156)-248-0774 |
| User ID | KATHRYN CAMPUZANO |
| Facility ID | 2089 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Comments | Surgeon is board certified cardio thoracic attends tumor boards but does not have an office in our cancer center |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | No |
| Comments | surgeon is cardio-thoracic board certified |
| Name | Kathryn Campuzano |
| Title | Thoracic Oncology/Screening Nurse Navigator |
| KCampuzano@memorialcare.org | |
| Phone | (156)-248-0774 |
| User ID | KATHRYN CAMPUZANO |
| Facility ID | 2089 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kitty Campuzano |
| Title | Thoracic Oncology/Screening Nurse Navigator |
| kathryn.mhc@gmail.com | |
| Phone | (562)-235-0638 |
| User ID | KATHRYN CAMPUZANO |
| Facility ID | 2089 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Tia Cantrell, BS RTR.M.CT |
| Title | Program Manager Lung Screening and Incidentals |
| tia.cantrell@advocatehealth.org | |
| Phone | (828)-455-0107 |
| User ID | Tia cantrell |
| Facility ID | 2087 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Tia Cantrell, BS RTR.M.CT |
| Title | Program Manager Lung Screening and Incidentals |
| tia.cantrell@advocatehealth.org | |
| Phone | (828)-455-0107 |
| User ID | Tia cantrell |
| Facility ID | 2086 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Tia Cantrell, BS RTR.M.CT |
| Title | Program Manager Lung Screening and Incidentals |
| tia.cantrell@advocatehealth.org | |
| Phone | (828)-455-0107 |
| User ID | Tia cantrell |
| Facility ID | 2085 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Tia Cantrell, BS RTR.M.CT |
| Title | Program Manager Lung Screening and Incidentals |
| tia.cantrell@advocatehealth.org | |
| Phone | (828)-455-0107 |
| User ID | Tia cantrell |
| Facility ID | 2084 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Tia Cantrell, BS RTR.M.CT |
| Title | Program Manager Lung Screening and Incidentals |
| tia.cantrell@advocatehealth.org | |
| Phone | (828)-455-0107 |
| User ID | Tia cantrell |
| Facility ID | 2083 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Tia Cantrell, BS RTR.M.CT |
| Title | Program Manager Lung Screening and Incidentals |
| tia.cantrell@advocatehealth.org | |
| Phone | (828)-455-0107 |
| User ID | Tia cantrell |
| Facility ID | 2081 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Tia Cantrell, BS RTR.M.CT |
| Title | Program Manager Lung Screening and Incidentals |
| tia.cantrell@advocatehealth.org | |
| Phone | (828)-455-0107 |
| User ID | Tia cantrell |
| Facility ID | 2081 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Tia Cantrell, BS RTR.M.CT |
| Title | Program Manager Lung Screening and Incidentals |
| tia.cantrell@advocatehealth.org | |
| Phone | (828)-455-0107 |
| User ID | Tia cantrell |
| Facility ID | 2082 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Tia Cantrell, BS RTR.M.CT |
| Title | Program Manager Lung Screening and Incidentals |
| tia.cantrell@advocatehealth.org | |
| Phone | (828)-455-0107 |
| User ID | Tia cantrell |
| Facility ID | 2082 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Tia Cantrell, BS RTR.M.CT |
| Title | Program Manager Lung Screening and Incidentals |
| tia.cantrell@advocatehealth.org | |
| Phone | (828)-455-0107 |
| User ID | Tia cantrell |
| Facility ID | 1543 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Tia Cantrell, BS RTR.M.CT |
| Title | Program Manager Lung Screening and Incidentals |
| tia.cantrell@advocatehealth.org | |
| Phone | (828)-455-0107 |
| User ID | Tia cantrell |
| Facility ID | 1543 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Tia Cantrell, BS RTR.M.CT |
| Title | Program Manager Lung Screening and Incidentals |
| tia.cantrell@advocatehealth.org | |
| Phone | (828)-455-0107 |
| User ID | Tia cantrell |
| Facility ID | 1542 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Tia Cantrell, BS RTR.M.CT |
| Title | Program Manager Lung Screening and Incidentals |
| tia.cantrell@advocatehealth.org | |
| Phone | (828)-455-0107 |
| User ID | Tia cantrell |
| Facility ID | 1542 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Tia Cantrell, BS RTR.M.CT |
| Title | Program Manager Lung Screening and Incidentals |
| tia.cantrell@advocatehealth.org | |
| Phone | (828)-455-0107 |
| User ID | Tia cantrell |
| Facility ID | 1194 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Tia Cantrell, BS RTR.M.CT |
| Title | Program Manager Lung Screening and Incidentals |
| tia.cantrell@advocatehealth.org | |
| Phone | (828)-455-0107 |
| User ID | Tia cantrell |
| Facility ID | 1194 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Tia Cantrell |
| Title | Program Manager |
| tia.cantrell@advocatehealth.org | |
| Phone | (828)-455-0107 |
| User ID | Tia cantrell |
| Facility ID | 1544 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amy Cornelison |
| Title | Advanced Imaging Manager |
| Amy.Cornelison@coxhealth.com | |
| Phone | (417)-269-1233 |
| User ID | Kim McMillian |
| Facility ID | 1750 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amy Cornelison |
| Title | Advanced Imaging Manager |
| Amy.Cornelison@coxhealth.com | |
| Phone | (417)-269-1233 |
| User ID | Kim McMillian |
| Facility ID | 2061 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amy Cornelison |
| Title | Advanced Imaging Manager |
| Amy.Cornelison@coxhealth.com | |
| Phone | (417)-269-1233 |
| User ID | Kim McMillian |
| Facility ID | 2062 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Sherri Hoag |
| Title | Lung Cancer Nurse Navigator |
| shoag@memorialcare.org | |
| Phone | (949)-452-7416 |
| User ID | Sheri Hoag |
| Facility ID | 1199 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Liliana Parra |
| Title | Director Lung Health Institute |
| liliana.parra@adventhealth.com | |
| Phone | (321)-276-9696 |
| User ID | Lili Parra |
| Facility ID | 1935 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Dr Jennifer Crow |
| Title | Pathologist |
| Jennifer.crow@adventhealth.com | |
| Phone | (682)-317-8173 |
| User ID | Lynnette Roberts |
| Facility ID | 2078 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Comments | Structured Incidental Lung Nodule program in place |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Comments | ILN Program in place |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Kristy Robinson |
| Title | Oncology Clinical Coordinator |
| kristy.robinson.aprn@adventhealth.com | |
| Phone | (817)-551-5312 |
| User ID | Lynnette Roberts |
| Facility ID | 2078 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Comments | On site oncology APRN, navigator and Oncology Center |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Kristy Robinson |
| Title | Clinical Oncology Coordinator |
| Kristy.robinson.aprn@adventhealth.com | |
| Phone | (817)-551-5312 |
| User ID | Lynnette Roberts |
| Facility ID | 2078 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Comments | Biweekly Tumor Board meeting |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Comments | Tumor Board |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Lynnette Roberts |
| Title | Director Outpatient Surgery, Endoscopy, Bronchoscopy |
| lynnette.roberts@adventhealth.com | |
| Phone | (817)-551-2459 |
| User ID | Lynnette Roberts |
| Facility ID | 2078 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Comments | ACR LCSR |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Dr. Ben Wandkte |
| Title | MD, MS |
| Ben_Wandtke@urmc.rochester.edu | |
| Phone | (585)-396-6633 |
| User ID | Mary Jo Evans |
| Facility ID | 2079 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Jennifer Kummerfeldt |
| Title | Director of Population Health |
| jkummerfeldt@masongeneral.com | |
| Phone | (360)-426-2653 |
| User ID | Jennifer Kummerfeldt |
| Facility ID | 2077 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| Comments | Test |
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Comments | Test |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Comments | Test |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Comments | Test |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Comments | Test |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Comments | Test |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Comments | Test |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Comments | Test |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Comments | Test |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Comments | Test |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Comments | Test |
| Name | Angela Bluebarry Barry |
| Title | test subject |
| acriswell4051@gmail.com | |
| Phone | (502)-682-7745 |
| User ID | Angela Criswell-Barry |
| Facility ID | 1038 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Shannon Little |
| Title | Manager |
| shannon.little@ascension.org | |
| Phone | (316)-268-5854 |
| User ID | Keisha Humphries |
| Facility ID | 1869 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Shannon Little |
| Title | Manager |
| Shannon.little@ascension.org | |
| Phone | (316)-268-5348 |
| User ID | Keisha Humphries |
| Facility ID | 1869 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Shannon Little |
| Title | Manager |
| shannon.little@ascension.org | |
| Phone | (316)-268-5348 |
| User ID | Keisha Humphries |
| Facility ID | 1869 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Shannon Little |
| Title | Manager |
| shannon.little@ascension.org | |
| Phone | (316)-268-5348 |
| User ID | Keisha Humphries |
| Facility ID | 1869 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Julie Jarvis |
| Title | Director of Operations |
| julie.jarvis@integrishealth.org | |
| Phone | (405)-773-6406 |
| User ID | Nathaniel Moulton |
| Facility ID | 2000 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jordan Fein, MD and Leslie Sorenson |
| Title | Medical Director and Manager |
| lmsorens@lhs.org | |
| Phone | (503)-413-8446 |
| User ID | Leslie Sorenson |
| Facility ID | 2065 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Danielle Henricksen |
| Title | Cancer Program Director |
| Danielle.Henricksen@bryanhealth.org | |
| Phone | (402)-481-7900 |
| User ID | Angela Burchett |
| Facility ID | 1929 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Danielle Henricksen |
| Title | Cancer Program Director |
| Danielle.Henricksen@bryanhealth.org | |
| Phone | (402)-481-7900 |
| User ID | Angela Burchett |
| Facility ID | 1929 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | No |
| Collect and review internal clinical outcomes in a quality improvement process. | No |
| Calculated Section Total | 7 |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Sharon Harms |
| Title | Radiology/GI Specialties Director |
| Sharon.Harms@bryanhealth.org | |
| Phone | (402)-481-3901 |
| User ID | Angela Burchett |
| Facility ID | 1929 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jillian Eastman |
| Title | Nurse Practitioner |
| jeastman@hoacny.com | |
| Phone | (315)-472-7504 |
| User ID | Jillian Eastman |
| Facility ID | 2064 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | No |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 6 |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Andrea Gresnick |
| Title | CT Technologist |
| agresnick@cassregional.org | |
| Phone | (816)-887-0377 |
| User ID | ANDREA GRESNICK |
| Facility ID | 2070 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | No |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 8 |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Andrea Gresnick |
| Title | CT Technologist |
| agresnick@cassregional.org | |
| Phone | (816)-887-0377 |
| User ID | ANDREA GRESNICK |
| Facility ID | 2070 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | No |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 6 |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Andrea Gresnick |
| Title | CT Technologist |
| agresnick@cassregional.org | |
| Phone | (816)-887-0377 |
| User ID | ANDREA GRESNICK |
| Facility ID | 2071 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | No |
| Comments | Would like more information on this |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Comments | Radloop |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 8 |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Andrea Gresnick |
| Title | CT Technologist |
| agresnick@cassregional.org | |
| Phone | (816)-887-0377 |
| User ID | ANDREA GRESNICK |
| Facility ID | 2071 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1607 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1607 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1606 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1606 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1605 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1605 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1604 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1604 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1617 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1617 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1610 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1610 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1616 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1612 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1612 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1621 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1621 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1609 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1609 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1608 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1608 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1622 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1622 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1615 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1615 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1620 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1620 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1611 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1611 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1614 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1614 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1603 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| Leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1603 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1619 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1619 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1613 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1613 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@advocatehealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1618 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1618 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Leisa Lackey |
| Title | Director |
| leisa.lackey@atriumhealth.org | |
| Phone | (704)-446-8574 |
| User ID | leisa lackey |
| Facility ID | 1616 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Krystle Pew |
| Title | LCS Director |
| Krystle.Pew@va.gov | |
| Phone | (205)-933-8101 |
| User ID | Sasha Smith |
| Facility ID | 1812 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Deepankar Sharma |
| Title | Interventional Pulmonologist, Medical Director - Lung Institute |
| dsharma@crh.org | |
| Phone | (443)-835-5863 |
| User ID | Deepankar Sharma |
| Facility ID | 2063 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Deepankar Sharma |
| Title | Interventional Pulmonologist, Medical Director - Lung Institute |
| dsharma@crh.org | |
| Phone | (443)-835-5863 |
| User ID | Deepankar Sharma |
| Facility ID | 2063 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Amie J. Miller |
| Title | APRN |
| amie-miller@smh.com | |
| Phone | (941)-917-6203 |
| User ID | Amie Miller |
| Facility ID | 1400 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | No |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 8 |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amie J. Miller Miller |
| Title | APRN |
| amie-miller@smh.com | |
| Phone | (941)-917-6203 |
| User ID | Amie Miller |
| Facility ID | 1400 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jenn Bainey |
| Title | Lung Health Navigator |
| jbainey@conemaugh.org | |
| Phone | (814)-534-5212 |
| User ID | Jenn Bainey |
| Facility ID | 1627 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jenn Bainey |
| Title | Lung Health Navigator |
| jbainey@conemaugh.org | |
| Phone | (814)-534-5212 |
| User ID | Jenn Bainey |
| Facility ID | 1243 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Tram Nguyen |
| Title | NP |
| tram.nguyen4@va.gov | |
| Phone | (858)-642-3917 |
| User ID | Lana Sheinkman |
| Facility ID | 1851 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jordan Fein, MD and Leslie Sorenson |
| Title | Director and Manager |
| lmsorens@lhs.org | |
| Phone | (503)-413-8050 |
| User ID | Leslie Sorenson |
| Facility ID | 1858 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jordan Fein, MD and Leslie Sorenson |
| Title | Director and Manager |
| lmsorens@Lhs.org | |
| Phone | (503)-413-8050 |
| User ID | Leslie Sorenson |
| Facility ID | 1716 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jordan Fein, MD and Leslie Sorenson |
| Title | Director and Manager |
| lmsorens@lhs.org | |
| Phone | (503)-413-8050 |
| User ID | Leslie Sorenson |
| Facility ID | 1123 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Jackie Muenks |
| Title | Director Outpatient Radiology |
| Jackie.Muenks@coxhealth.com | |
| Phone | (417)-268-8543 |
| User ID | Kim McMillian |
| Facility ID | 1751 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Lisa Allen |
| Title | Thoracic & Foregut Oncology Navigator |
| lallen@mercy.com | |
| Phone | (513)-215-9766 |
| User ID | Marquisse Watson |
| Facility ID | 1358 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Nicole Vogelsang |
| Title | Lung Navigator |
| nrvogelsang@mercy.com | |
| Phone | (513)-478-7706 |
| User ID | Marquisse Watson |
| Facility ID | 1358 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Comments | Fleischner criteria as reviewed by dedicated Thoracic radiologists |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Comments | Multidisciplinary Thoracic Oncology tumor board with Thoracic Radiology, Thoracic surgery, Radiation Oncology, Interventional Pulmonology, Thoracic Oncology and Pathology |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Comments | EMR-based solution with documentation of Tumor Board input and reporting to referring physicians. |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Comments | Routine component of standardized Interventional Pulmonary clinic assessment |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Comments | Epic alerts are used to alert ordering providers if an incidental nodule warranting follow up is present with specific recommendations for follow-up (e.g. refer to Pulmonology, Thoracic surgery, etc) |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | No |
| Name | Vivek Murthy, MD |
| Title | Director, Bellevue Lung Cancer Screening Program |
| murthyv@nychhc.org | |
| Phone | (347)-346-3776 |
| User ID | Vivek Murthy |
| Facility ID | 1999 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| Comments | USPSTF Criteria |
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Comments | Shared decision making documentation is required to proceed with LCS, embedded into our EMR orderset and documented in a standardized note for all patients. |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Comments | LungRADS standard reporting |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Comments | Bellevue Thoracic Oncology Tumor Board review of all screen-positive cases involving Thoracic surgery, Thoracic radiology, Radiation Oncology, Thoracic Oncology, Interventional Pulmonology and Pathology in addition to the LCS Navigator. |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Comments | EMR-based standardized workflow |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Comments | Cessation services offered within a dedicated LCS clinic. |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Comments | EMR-based solution for centralized (system-wide) monitoring of results, follow-up plan and alerts when scans/interventions are due. |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Comments | EMR-based solution (Epic Lung nodule) |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Vivek Murthy |
| Title | Director, Bellevue Lung Cancer Screening Program |
| murthyv@nychhc.org | |
| Phone | (347)-346-3776 |
| User ID | Vivek Murthy |
| Facility ID | 1999 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| Comments | We screen BTMed pts but do not send them to ACR NRDR LCSR |
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | No |
| Comments | Smoking Cessation is managed by PC and Pulm. We are currently working on cessation brochure for imaging sites |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 8 |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Comments | LCSR |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Comments | annually |
| Name | Trent West |
| Title | Lung Screening Manager |
| t1west@saint-lukes.org | |
| Phone | (913)-940-1191 |
| User ID | Trent West |
| Facility ID | 1629 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | No |
| Comments | Unknown |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | No |
| Comments | Unknown |
| Name | Ashley Nettles |
| Title | LCS Coordianator |
| ashgraff@med.umich.edu | |
| Phone | (734)-998-6326 |
| User ID | Ashley Nettles |
| Facility ID | 1962 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Jennifer Hellmuth |
| Title | RN Navigator |
| jhellmut@med.umich.edu | |
| Phone | (734)-936-5661 |
| User ID | Ashley Nettles |
| Facility ID | 1962 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| Comments | SDM prior to order placement and DT when scheduling |
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Comments | Prior to order placement |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Comments | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Comments | LungRads |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Comments | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Ashley Nettles |
| Title | LCS Coordinator |
| ashgraff@med.umich.edu | |
| Phone | (734)-998-6326 |
| User ID | Ashley Nettles |
| Facility ID | 1962 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Laura Kuzma MSW |
| Title | Administrative Director, Oncology Services |
| lkuzma@firsthealth.org | |
| Phone | (910)-715-2298 |
| User ID | Kim Cobb |
| Facility ID | 1296 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Comments | In process of applying for ACR accreditation as well and will then be reporting to ACR registry |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Comments | We do so at weekly huddles and via Epic Lung |
| Name | Alfredo Astua |
| Title | Chief of Pulmonary and Critical Care |
| astuaa@nychhc.org | |
| Phone | (917)-957-2242 |
| User ID | alfredo astua |
| Facility ID | 2052 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Joanna Thompson |
| Title | Director, LCSP & Multidisciplinary Programs |
| jthompson@hogonc.com | |
| Phone | (479)-587-1700 |
| User ID | Joanna Thompson |
| Facility ID | 1126 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Lacey Phelps |
| Title | Oncology Clinical Practice Manager |
| phelln@mchealth.net | |
| Phone | (270)-745-1069 |
| User ID | Jennifer Finch |
| Facility ID | 2029 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | No |
| Comments | We have board certified cardiothoracic surgeons but they are not Thoracic oncologists |
| Name | Lacey Phelps |
| Title | Oncology Clinical Practice Manager |
| phelln@mchealth.net | |
| Phone | (270)-745-1069 |
| User ID | Jennifer Finch |
| Facility ID | 2029 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Alexis B. Paulson, MSN, APRN |
| Title | Lung Screening Program Coordinator |
| alexis.paulson@commonspirit.org | |
| Phone | (805)-346-3463 |
| User ID | Alexis Paulson |
| Facility ID | 1301 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Jennifer Finch |
| Title | VP of Supply Chain |
| fincjl@mchealth.net | |
| Phone | (270)-745-1224 |
| User ID | Jennifer Finch |
| Facility ID | 2029 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Keaona Adkinson |
| Title | Director of Oncology Services |
| keaona_adkinson@grandviewhealth.com | |
| Phone | (205)-971-1802 |
| User ID | Kristi Denny |
| Facility ID | 1873 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Keaona Adkinson |
| Title | Director of Oncology |
| keaona_adkinson@grandviewhealth.com | |
| Phone | (205)-971-1802 |
| User ID | Kristi Denny |
| Facility ID | 1873 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Kristi Denny |
| Title | Navigator |
| kristi_denny@grandviewhealth.com | |
| Phone | (205)-971-1805 |
| User ID | Kristi Denny |
| Facility ID | 1873 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Keaona Adkinson |
| Title | Director of Oncology |
| keaona_adkinson@grandviewhealth.com | |
| Phone | (205)-971-1802 |
| User ID | Kristi Denny |
| Facility ID | 1873 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Catrina Linn Mellen Gilstrap |
| Title | Nurse Navigator |
| catrina.gilstrap@mercy.net | |
| Phone | (417)-556-2714 |
| User ID | Catrina Gilstrap |
| Facility ID | 1429 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Comments | We utilize Fleischner Society Guidelines. |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Comments | Weekly lung nodule team conference with pulmonary, interventional pulmonary, thoracic surgery, navigation. |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Comments | Utilizing the EON platform for IPN we have standardized templated letters that both patients and providers receive upon identification of a IPN that is consider of high risk an needs to be followed. |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Comments | Upon verification of current smoking status patients are advised to quit and are given appropriate resources to free services. |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Comments | As per on our radiology reports, This exam was performed according to our departmental dose-optimization program which includes automated exposure control, adjustment of the mA and/or kV according to patient size and/or use of iterative reconstruction technique. |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Comments | We unitize the EON tracking software to ensure proper follow up and adherence to guidelines |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Comments | Quarterly adherence reports provided by EON software, along with metrics from the time finding to definitive treatment are reviewed routinely for quality improvement. |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Comments | Most IPN are captured with the EON AI software. With other IPN entering the program Other points of enter exist however, work flows are not as streamlined and rely on word of mouth, facts, phone call or email notification. We hope to improve this process once our health care system fully integrates into the EPIC EMR. |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Comments | We utilize the EON platform for all tracking and identifying of IPNs |
| Name | Rona Seiple |
| Title | Incidental Pulmonary Nodule Program Coordinator |
| rona-seiple@smh.com | |
| Phone | (941)-917-6236 |
| User ID | Rona Seiple |
| Facility ID | 1400 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Maggie Smith |
| Title | RN/Director |
| margaret.smith610@commonspirit.org | |
| Phone | (502)-507-5715 |
| User ID | Emily May |
| Facility ID | 1468 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Maggie Smith |
| Title | RN/Director |
| margaret.smith610@commonspirit.org | |
| Phone | (502)-507-5715 |
| User ID | Emily May |
| Facility ID | 1468 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Deanna Wigginton |
| Title | APRN |
| deanna.wigginton@commonspirit.org | |
| Phone | (859)-421-6195 |
| User ID | Emily May |
| Facility ID | 1469 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Deanna Wigginton |
| Title | APRN |
| deanna.wigginton@commonspirit.org | |
| Phone | (859)-421-6195 |
| User ID | Emily May |
| Facility ID | 1567 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Deanna Wigginton |
| Title | APRN |
| deanna.wigginton@commonspirit.org | |
| Phone | (859)-421-6195 |
| User ID | Emily May |
| Facility ID | 1250 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Maggie Smith |
| Title | RN/Director |
| margaret.smith610@commonspirit.org | |
| Phone | (502)-507-5715 |
| User ID | Emily May |
| Facility ID | 1255 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Maggie Smith |
| Title | RN/Director |
| margaret.smith610@commonspirit.org | |
| Phone | (502)-507-5715 |
| User ID | Emily May |
| Facility ID | 1255 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Deanna Wigginton |
| Title | APRN |
| deanna.wigginton@commonspirit.org | |
| Phone | (859)-421-6195 |
| User ID | Emily May |
| Facility ID | 1254 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Deanna Wigginton |
| Title | APRN |
| deanna.wigginton@commonspirit.org | |
| Phone | (859)-421-6195 |
| User ID | Emily May |
| Facility ID | 1252 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Deanna Wigginton |
| Title | APRN |
| deanna.wigginton@commonspirit.org | |
| Phone | (859)-421-6195 |
| User ID | Emily May |
| Facility ID | 1256 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Maggie Smith |
| Title | RN |
| margaret.smith610@commonspirit.org | |
| Phone | (502)-507-5715 |
| User ID | Emily May |
| Facility ID | 1251 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Deanna Wigginton |
| Title | APRN |
| deanna.wigginton@commonspirit.org | |
| Phone | (859)-421-6195 |
| User ID | Emily May |
| Facility ID | 1251 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Deanna Wigginton |
| Title | APRN |
| deanna.wigginton@commonspirit.org | |
| Phone | (859)-421-6195 |
| User ID | Emily May |
| Facility ID | 1249 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Deanna Wigginton |
| Title | APRN |
| deanna.wigginton@commonspirit.org | |
| Phone | (859)-421-6195 |
| User ID | Emily May |
| Facility ID | 1249 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Deanna Wigginton |
| Title | APRN |
| deanna.wigginton@commonspirit.org | |
| Phone | (859)-421-6195 |
| User ID | Emily May |
| Facility ID | 1467 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Deanna Wigginton |
| Title | APRN |
| deanna.wigginton@commonspirit.org | |
| Phone | (859)-421-6195 |
| User ID | Emily May |
| Facility ID | 1253 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Comments | Nodule clinic is staffed by Thoracic team and Pulmonary Medicine with a lung cancer MDC in place |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Comments | Standardized process in place for both |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Comments | Program integrated with our EMR to ensure follow up is completed |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Comments | Internal report is generated weekly, and reporting system has been established with for profit outside radiology center to capture those IPN's as well |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Comments | Radiology department uses incidental nodule code for any nodules seen on any imaging modality |
| Name | Tammy Welch, PA-C |
| Title | Program Coordinator Early Pulmonary Cancer Detection Program |
| twelch@frederick.health | |
| Phone | (301)-694-5861 |
| User ID | Maurice Smith |
| Facility ID | 2018 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Yaron Perry MD, FACS |
| Title | Division Chief - Thoracic Surgery |
| yperry@buffalo.edu | |
| Phone | (716)-859-7937 |
| User ID | Yaron Perry |
| Facility ID | 1934 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcia Tengwall |
| Title | Lung Cancer Screening Program Navigator |
| Marcia.Tengwall@providence.org | |
| Phone | (971)-358-0942 |
| User ID | Marcia Tengwall |
| Facility ID | 1275 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcia Tengwall |
| Title | Lung Cancer Screening Program Navigator |
| Marcia.Tengwall@providence.org | |
| Phone | (971)-358-0942 |
| User ID | Marcia Tengwall |
| Facility ID | 1274 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcia Tengwall |
| Title | Lung Cancer Screening Program Navigator |
| Marcia.Tengwall@providence.org | |
| Phone | (971)-358-0942 |
| User ID | Marcia Tengwall |
| Facility ID | 1273 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcia Tengwall |
| Title | Lung Cancer Screening Program Navigator |
| Marcia.Tengwall@providence.org | |
| Phone | (971)-358-0942 |
| User ID | Marcia Tengwall |
| Facility ID | 1512 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcia Tengwall |
| Title | Lung Cancer Screening Program Navigator |
| Marcia.Tengwall@providence.org | |
| Phone | (971)-358-0942 |
| User ID | Marcia Tengwall |
| Facility ID | 1272 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcia Tengwall |
| Title | Lung Cancer Screening Program Navigator |
| Marcia.Tengwall@providence.org | |
| Phone | (971)-358-0942 |
| User ID | Marcia Tengwall |
| Facility ID | 1271 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcia Tengwall |
| Title | Lung Cancer Screening Program Navigator |
| Marcia.Tengwall@providence.org | |
| Phone | (971)-358-0942 |
| User ID | Marcia Tengwall |
| Facility ID | 1509 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcia Tengwall |
| Title | Lung Cancer Screening Program Navigator |
| Marcia.Tengwall@providence.org | |
| Phone | (971)-358-0942 |
| User ID | Marcia Tengwall |
| Facility ID | 1510 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcia Tengwall |
| Title | Lung Cancer Screening Program Navigator |
| Marcia.Tengwall@providence.org | |
| Phone | (971)-358-0942 |
| User ID | Marcia Tengwall |
| Facility ID | 1511 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Rochelle Waddell |
| Title | Service Line Coordinator for Lung Cancer Screening |
| rwaddell@arh.org | |
| Phone | (606)-439-6981 |
| User ID | Rochelle Waddell |
| Facility ID | 1885 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Rochelle Waddell |
| Title | Service Line Coordinator for Lung Cancer Screening |
| rwaddell@arh.org | |
| Phone | (606)-439-6981 |
| User ID | Rochelle Waddell |
| Facility ID | 1897 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Rochelle Waddell |
| Title | Service Line Coordinator for Lung Cancer Screening |
| rwaddell@arh.org | |
| Phone | (606)-439-6981 |
| User ID | Rochelle Waddell |
| Facility ID | 1907 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Rochelle Waddell |
| Title | Service Line Coordinator for Lung Cancer Screening |
| rwaddell@arh.org | |
| Phone | (606)-439-6981 |
| User ID | Rochelle Waddell |
| Facility ID | 1901 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Rochelle Waddell |
| Title | Service Line Coordinator for Lung Cancer Screening |
| rwaddell@arh.org | |
| Phone | (606)-439-6981 |
| User ID | Rochelle Waddell |
| Facility ID | 1900 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Rochelle Waddell |
| Title | Service Line Coordinator for Lung Cancer Screening |
| rwaddell@arh.org | |
| Phone | (606)-439-6981 |
| User ID | Rochelle Waddell |
| Facility ID | 1886 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Rochelle Waddell |
| Title | Service Line Coordinator for Lung Cancer Screening |
| rwaddell@arh.org | |
| Phone | (606)-439-6981 |
| User ID | Rochelle Waddell |
| Facility ID | 1898 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Rochelle Waddell |
| Title | Service Line Coordinator for Lung Cancer Screening |
| rwaddell@arh.org | |
| Phone | (606)-439-6981 |
| User ID | Rochelle Waddell |
| Facility ID | 1899 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Rochelle Waddell |
| Title | Service Line Coordinator for Lung Cancer Screening |
| rwaddell@arh.org | |
| Phone | (606)-439-6981 |
| User ID | Rochelle Waddell |
| Facility ID | 1887 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Rochelle Waddell |
| Title | Service Line Coordinator for Lung Cancer Screening |
| rwaddell@arh.org | |
| Phone | (606)-439-6981 |
| User ID | Rochelle Waddell |
| Facility ID | 1895 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Rochelle Waddell |
| Title | Service Line Coordinator for Lung Cancer Screening |
| rwaddell@arh.org | |
| Phone | (606)-439-6981 |
| User ID | Rochelle Waddell |
| Facility ID | 1908 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Rochelle Waddell |
| Title | Service Line Coordinator for Lung Cancer Screening |
| rwaddell@arh.org | |
| Phone | (606)-439-6981 |
| User ID | Rochelle Waddell |
| Facility ID | 1896 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Rochelle Waddell |
| Title | Service Line Coordinator for Lung Cancer Screening |
| rwaddell@arh.org | |
| Phone | (606)-439-6981 |
| User ID | Rochelle Waddell |
| Facility ID | 1888 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Rochelle Waddell |
| Title | Service Line Coordinator for Lung Cancer Screening |
| rwaddell@arh.org | |
| Phone | (606)-439-6981 |
| User ID | Rochelle Waddell |
| Facility ID | 1257 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Deanna Wigginton |
| Title | Lung Navigator/APRN |
| deanna.wigginton@commonspirit.org | |
| Phone | (859)-421-6195 |
| User ID | Emily May |
| Facility ID | 1893 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jennifer Bainey |
| Title | Lung Health Navigator |
| jbainey@conemaugh.org | |
| Phone | (814)-534-5212 |
| User ID | Deb Hegedus |
| Facility ID | 1835 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jennifer Bainey |
| Title | Lung Health Navigator |
| jbainey@conemaugh.org | |
| Phone | (814)-534-5212 |
| User ID | Deb Hegedus |
| Facility ID | 1910 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | No |
| Comments | Patients are referred back to their primary care physician to discuss the best management options for them. |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 8 |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Lauren Figland |
| Title | Radiology Manager |
| lauren.figland@mercyoneiowa.org | |
| Phone | (641)-792-1273 |
| User ID | Julie Hauber |
| Facility ID | 1558 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Michelle Ottersbach |
| Title | Nurse Navigator/Consultant |
| michelle_ottersbach@med.unc.edu | |
| Phone | (919)-843-2277 |
| User ID | Michelle Ottersbach |
| Facility ID | 2042 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Michelle Ottersbach |
| Title | Nurse Navigator/Consultant |
| michelle_ottersbach@med.unc.edu | |
| Phone | (919)-843-2277 |
| User ID | Michelle Ottersbach |
| Facility ID | 1876 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Michelle Ottersbach |
| Title | Nurse Navigator/Consultant |
| michelle_ottersbach@med.unc.edu | |
| Phone | (919)-843-2277 |
| User ID | Michelle Ottersbach |
| Facility ID | 1877 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Michelle Ottersbach |
| Title | Nurse Navigator/Consultant |
| michelle_ottersbach@med.unc.edu | |
| Phone | (919)-843-2277 |
| User ID | Michelle Ottersbach |
| Facility ID | 1875 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Michelle Ottersbach |
| Title | consultant |
| michelle_ottersbach@med.unc.edu | |
| Phone | (919)-843-2277 |
| User ID | Michelle Ottersbach |
| Facility ID | 1878 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Katie Ratcliff |
| Title | Quality Coordinator |
| kratcliff@iuhealth.org | |
| Phone | (317)-605-8021 |
| User ID | katie ratcliff |
| Facility ID | 2010 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Ashley Bleier |
| Title | Program Coordinator |
| ashley.bleier@rochesterregional.org | |
| Phone | (585)-922-1467 |
| User ID | Ashley Bleier |
| Facility ID | 1821 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Dr. Enise Yoo-Liu |
| Title | MD |
| enise.yoo-liu@commonspirit.org | |
| Phone | (602)-406-4551 |
| User ID | Cindy Stotts |
| Facility ID | 1019 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sarah Groce, NP |
| Title | NP |
| sarah.groce@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 2041 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sarah Groce, NP |
| Title | NP |
| sarah.groce@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 2040 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sarah Groce, NP |
| Title | NP |
| sarah.groce@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 2039 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sarah Groce, NP |
| Title | NP |
| sarah.groce@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 2038 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sarah Groce, NP |
| Title | NP |
| sarah.groce@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 2037 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sarah Groce, NP |
| Title | NP |
| sarah.groce@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 2036 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sarah Groce, NP |
| Title | NP |
| sarah.groce@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 1374 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sarah Groce, NP |
| Title | NP |
| sarah.groce@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 1371 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sarah Groce, NP |
| Title | NP |
| sarah.groce@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 1370 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sarah Groce, NP |
| Title | NP |
| sarah.groce@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 2030 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Matthew Manning |
| Title | MD |
| matthew.manning@conehealth.com | |
| Phone | (336)-832-1100 |
| User ID | Denise phelps |
| Facility ID | 1713 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sarah Groce, NP |
| Title | NP |
| sarah.groce@conehealth.com | |
| Phone | (336)-522-8921 |
| User ID | Denise phelps |
| Facility ID | 1713 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Sarah Groce |
| Title | AGAC-NP |
| sarah.groce@conehealth.com | |
| Phone | (336)-340-3090 |
| User ID | Sarah Groce |
| Facility ID | 1369 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Sandra Jennings |
| Title | Director of Oncology Support & Education |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 1396 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sandra Jennings |
| Title | Director of Oncology Support & Education |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 1396 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Sandra Jennings |
| Title | Director of Oncology Support & Education |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 1395 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sandra Jennings |
| Title | Director of Oncology Support & Education |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 1395 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Sandra Jennings |
| Title | Director of Oncology Support & Education |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 1394 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sandra Jennings |
| Title | Director of Oncology Support & Education |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 1394 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Sandra Jennings |
| Title | EF - Director of Oncology Support & Education |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 1958 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sandra Jennings |
| Title | EF- Director of Oncology Support & Education |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 1958 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Sandra Jennings |
| Title | EF-Director of Oncology Support & Education |
| sandra.jennings@adventhealth.com | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 1397 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sandra Jennings |
| Title | EF - Director of Oncology Support & Education |
| sandra.jennings@adventhealth.coom | |
| Phone | (386)-231-4032 |
| User ID | sandra Jennings |
| Facility ID | 1397 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Jennifer Adams Edwards, RN, BSN, OCN, TTS |
| Title | Lung Nodule Program Coordinator & Navigator |
| jedwards@wkhs.com | |
| Phone | (318)-455-3183 |
| User ID | Jennifer Edwards |
| Facility ID | 1723 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jennifer Adams Edwards, RN, BSN, OCN, TTS |
| Title | Lung Nodule Program Coordinator & Navigator |
| jedwards@wkhs.com | |
| Phone | (318)-455-3183 |
| User ID | Jennifer Edwards |
| Facility ID | 1723 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Jennifer Adams Edwards, RN, BSN, OCN, TTS |
| Title | Lung Nodule Program Coordinator & Navigator |
| jedwards@wkhs.com | |
| Phone | (318)-455-3183 |
| User ID | Jennifer Edwards |
| Facility ID | 1724 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jennifer Edwards, RN, BSN, OCN, TTS |
| Title | Lung Nodule Program Coordinator |
| jedwards@wkhs.com | |
| Phone | (318)-455-3183 |
| User ID | Jennifer Edwards |
| Facility ID | 1724 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcey Bowhuis |
| Title | RN |
| marceybowhuis@corewellhealth.org | |
| Phone | (616)-486-5993 |
| User ID | Marcey Bowhuis |
| Facility ID | 2034 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcey Bowhuis |
| Title | RN |
| marceybowhuis@corewellhealth.org | |
| Phone | (616)-486-5993 |
| User ID | Marcey Bowhuis |
| Facility ID | 2035 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcey Bowhuis |
| Title | RN |
| marceybowhuis@corewellhealth.org | |
| Phone | (616)-486-5993 |
| User ID | Marcey Bowhuis |
| Facility ID | 1414 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcey Bowhuis |
| Title | RN |
| marceybowhuis@corewellhealth.org | |
| Phone | (616)-486-5993 |
| User ID | Marcey Bowhuis |
| Facility ID | 1462 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcey Bowhuis |
| Title | RN |
| marceybowhuis@corewellhealth.org | |
| Phone | (616)-486-5993 |
| User ID | Marcey Bowhuis |
| Facility ID | 1458 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcey Bowhuis |
| Title | RN |
| marceybowhuis@corewellhealth.org | |
| Phone | (616)-486-5993 |
| User ID | Marcey Bowhuis |
| Facility ID | 1457 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcey Bowhuis |
| Title | RN |
| marceybowhuis@corewellhealth.org | |
| Phone | (616)-486-5993 |
| User ID | Marcey Bowhuis |
| Facility ID | 1561 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcey Bowhuis |
| Title | RN |
| marceybowhuis@corewellhealth.org | |
| Phone | (616)-486-5993 |
| User ID | Marcey Bowhuis |
| Facility ID | 1560 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcey Bowhuis |
| Title | RN |
| marceybowhuis@corewellhealth.org | |
| Phone | (616)-486-5993 |
| User ID | Marcey Bowhuis |
| Facility ID | 1460 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcey Bowhuis |
| Title | RN |
| marceybowhuis@corewellhealth.org | |
| Phone | (616)-486-5993 |
| User ID | Marcey Bowhuis |
| Facility ID | 1454 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Alykhan Nagji |
| Title | MD |
| anagji@kumc.edu | |
| Phone | (913)-588-9498 |
| User ID | Liza Kerr |
| Facility ID | 1096 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcey Bowhuis |
| Title | RN |
| marceybowhuis@corewellhealth.org | |
| Phone | (616)-486-5993 |
| User ID | Marcey Bowhuis |
| Facility ID | 1461 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcey Bowhuis |
| Title | RN |
| marceybowhuis@corewellhealth.org | |
| Phone | (616)-486-5993 |
| User ID | Marcey Bowhuis |
| Facility ID | 1459 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcey Bowhuis |
| Title | RN |
| marceybowhuis@corewellhealth.org | |
| Phone | (616)-486-5993 |
| User ID | Marcey Bowhuis |
| Facility ID | 1455 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcey Bowhuis |
| Title | RN |
| marceybowhuis@corewellhealth.org | |
| Phone | (616)-486-5993 |
| User ID | Marcey Bowhuis |
| Facility ID | 1452 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcey Bowhuis |
| Title | RN |
| marceybowhuis@corewellhealth.org | |
| Phone | (616)-486-5993 |
| User ID | Marcey Bowhuis |
| Facility ID | 1451 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Marcey Bowhuis |
| Title | RN |
| marceybowhuis@corewellhealth.org | |
| Phone | (616)-486-5993 |
| User ID | Marcey Bowhuis |
| Facility ID | 1453 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Marcia Tengwall |
| Title | Lung Cancer Screening Program Navigator |
| Marcia.Tengwall@providence.org | |
| Phone | (971)-358-0942 |
| User ID | Marcia Tengwall |
| Facility ID | 1149 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Kimberly Turnbull |
| Title | Administrative Operations Coordinator |
| kturnbull@gppconline.com | |
| Phone | (716)-465-7801 |
| User ID | Kimberly Turnbull |
| Facility ID | 1941 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Stephanie Terrell |
| Title | Lung Nurse Navigator |
| slterrell@mercy.com | |
| Phone | (513)-870-7738 |
| User ID | Stephanie Terrell |
| Facility ID | 1362 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Wendi Waugh |
| Title | Director of Cancer and Infusion Services |
| Waughw@somc.org | |
| Phone | (740)-356-7490 |
| User ID | Jenny Woodyard |
| Facility ID | 1361 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jennifer Woodyard |
| Title | Lung Health Navigatot |
| Woodyarj@somc.org | |
| Phone | (740)-356-6907 |
| User ID | Jenny Woodyard |
| Facility ID | 1361 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Comments | I believe this is done through our cancer center. |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Comments | Again I believe this is done through our cancer center. |
| Name | FELISHA HAUSWIRTH |
| Title | Lung health specialist |
| felishahauswirth@gmail.com | |
| Phone | (740)-701-2603 |
| User ID | Felisha Hauswirth |
| Facility ID | 1154 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Lisa McGuire |
| Title | Director of Oncology |
| Lisa.Mcguire@hcahealthcare.com | |
| Phone | (352)-496-2175 |
| User ID | Lisa McGuire |
| Facility ID | 1036 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Lisa McGuire |
| Title | Director of Oncology |
| Lisa.Mcguire@hcahealthcare.com | |
| Phone | (352)-496-2175 |
| User ID | Lisa McGuire |
| Facility ID | 1036 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Lisa McGuire |
| Title | Director of Oncology |
| Lisa.Mcguire@hcahealthcare.com | |
| Phone | (352)-496-2175 |
| User ID | Lisa McGuire |
| Facility ID | 1036 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Lisa McGuire |
| Title | Director of Oncology |
| Lisa.Mcguire@hcahealthcare.com | |
| Phone | (352)-496-2175 |
| User ID | Lisa McGuire |
| Facility ID | 1034 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| Comments | Yes, but we do not track outcomes from the oncology practices after initial treatment plan is not working. |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Comments | Yes, but we do not track outcomes from the oncology practices after initial treatment plan is not working. |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Lisa McGuire |
| Title | Director of Oncology |
| Lisa.Mcguire@hcahealthcare.com | |
| Phone | (352)-496-2175 |
| User ID | Lisa McGuire |
| Facility ID | 1035 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Lisa McGuire |
| Title | Director of Oncology |
| Lisa.Mcguire@hcahealthcare.com | |
| Phone | (352)-496-2175 |
| User ID | Lisa McGuire |
| Facility ID | 1035 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Lisa McGuire |
| Title | Director of Oncology |
| Lisa.Mcguire@hcahealthcare.com | |
| Phone | (352)-496-2175 |
| User ID | Lisa McGuire |
| Facility ID | 1035 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Lisa McGuire |
| Title | Director of Oncology |
| Lisa.Mcguire@hcahealthcare.com | |
| Phone | (352)-496-2175 |
| User ID | Lisa McGuire |
| Facility ID | 1035 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Arissa Munoz |
| Title | Clinical Programs Manager |
| arissa.munoz@ascension.org | |
| Phone | (850)-416-6639 |
| User ID | Arissa Munoz |
| Facility ID | 1644 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Emily May |
| Title | Director |
| emily.may@commonspirit.org | |
| Phone | (859)-492-7418 |
| User ID | Emily May |
| Facility ID | 1893 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Pamela Worthy |
| Title | Director of Cancer Coordination |
| pam.worthy@mcleodhealth.org | |
| Phone | (843)-777-5926 |
| User ID | Pam Worthy |
| Facility ID | 1904 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Pamela Worthy |
| Title | Director of Cancer Coordination |
| pam.worthy@mcleodhealth.org | |
| Phone | (843)-777-5926 |
| User ID | Pam Worthy |
| Facility ID | 1906 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Pamela Worthy |
| Title | Director of Cancer Coordination |
| pam.worthy@mcleodhealth.org | |
| Phone | (843)-777-5926 |
| User ID | Pam Worthy |
| Facility ID | 1903 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Pamela Worthy |
| Title | Director of Cancer Coordination |
| pam.worthy@mcleodhealth.org | |
| Phone | (843)-777-5926 |
| User ID | Pam Worthy |
| Facility ID | 1905 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Pamela Worthy |
| Title | Director of Cancer Coordination |
| pam.worthy@mcleodhealth.org | |
| Phone | (843)-777-5926 |
| User ID | Pam Worthy |
| Facility ID | 1902 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Pamela Worthy |
| Title | Director of Cancer Coordination |
| pam.worthy@mcleodhealth.org | |
| Phone | (843)-777-5926 |
| User ID | Pam Worthy |
| Facility ID | 1909 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Pamela Worthy |
| Title | Director of Cancer Coordination |
| pam.worthy@mcleodhealth.org | |
| Phone | (843)-777-5926 |
| User ID | Pam Worthy |
| Facility ID | 1909 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Pamela Worthy |
| Title | Director of Cancer Coordination |
| pam.worthy@mcleodhealth.org | |
| Phone | (843)-777-5926 |
| User ID | Pam Worthy |
| Facility ID | 1792 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Pamela Worthy |
| Title | Director of Cancer Coordination |
| pam.worthy@mcleodhealth.org | |
| Phone | (843)-777-5926 |
| User ID | Pam Worthy |
| Facility ID | 1792 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jennifer Finch |
| Title | VP of Supply Chain |
| fincjl@mchealth.net | |
| Phone | (270)-745-1224 |
| User ID | Jennifer Finch |
| Facility ID | 2029 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Sandy Kohut, RRT, Lead Lung Navigator |
| Title | RRT, Lead Lung Navigator |
| kohuts@summahealth.org | |
| Phone | (330)-375-6899 |
| User ID | Sandy Kohut |
| Facility ID | 1415 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Kristin Bohreer |
| Title | RN, Clinical Program Manager |
| kristin.bohreer@virginiamason.org | |
| Phone | (206)-287-6045 |
| User ID | Kristin Bohreer |
| Facility ID | 1032 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Comments | Our software is out of date and no longer being updated. |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kristin Bohreer |
| Title | RN, Clinical Program Manger |
| Kristin.Bohreer@virginiamason.org | |
| Phone | (206)-287-6045 |
| User ID | Kristin Bohreer |
| Facility ID | 1032 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Ashley LeBlanc |
| Title | Regional Service Line Nurse Manager |
| Ashley.LeBlanc@TrinityHealthOfNE.org | |
| Phone | (413)-748-7370 |
| User ID | Ashley LeBlanc |
| Facility ID | 1382 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Jennifer Finch |
| Title | VP of Supply Chain |
| fincjl@mchealth.net | |
| Phone | (270)-745-1224 |
| User ID | Jennifer Finch |
| Facility ID | 2021 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kacey Strovers BS,RS, RT(R)(CT)(M) |
| Title | Lung Cancer Screening and Imaging Coordinator |
| kacey.strovers@mercyoneiowa.org | |
| Phone | (515)-643-8248 |
| User ID | Kacey Strovers |
| Facility ID | 1554 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | No |
| Comments | We are a radiation center and do not treat patients with systemic treatment. |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | No |
| Comments | N/A we are a radiation center. |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 8 |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | No |
| Comments | We do not have Thoracic Oncologists at our facility. We do have board certified Thoracis Oncologists at another campus we refer to. |
| Name | Melissa Jane Clark |
| Title | RN, OCN, Lung Program Coordinator |
| melissa.jane.clark@adventhealth.com | |
| Phone | (863)-386-6475 |
| User ID | melissa Clark |
| Facility ID | 1912 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| Comments | VA Patients with occupational exposure are screened after vetting for eligibility is completed by the lung navigator. |
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Melissa Jane Clark |
| Title | RN, OCN, Lung Program Coordinator |
| melissa.jane.clark@adventhealth.com | |
| Phone | (863)-386-6475 |
| User ID | melissa Clark |
| Facility ID | 1912 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Janine Caswell |
| Title | Program Coordinator |
| caswellj@upstate.edu | |
| Phone | (315)-464-7460 |
| User ID | Janine Caswell |
| Facility ID | 1062 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Camille Kroger |
| Title | Lead CT Technologist |
| ckroger@aminj.com | |
| Phone | (609)-650-0005 |
| User ID | Camille Kroger |
| Facility ID | 1522 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Camille Kroger |
| Title | Lead CT Technologist |
| ckroger@aminj.com | |
| Phone | (609)-650-0005 |
| User ID | Camille Kroger |
| Facility ID | 1524 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Camille Kroger |
| Title | Lead CT Technologist |
| ckroger@aminj.com | |
| Phone | (609)-650-0005 |
| User ID | Camille Kroger |
| Facility ID | 1525 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Camille Kroger |
| Title | Lead CT Technologist |
| ckroger@aminj.com | |
| Phone | (609)-650-0005 |
| User ID | Camille Kroger |
| Facility ID | 1859 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Camille Kroger |
| Title | Lead CT Technologist |
| ckroger@aminj.com | |
| Phone | (609)-650-0005 |
| User ID | Camille Kroger |
| Facility ID | 1860 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Camille Kroger |
| Title | Lead CT Technologist |
| ckroger@aminj.com | |
| Phone | (609)-650-0005 |
| User ID | Camille Kroger |
| Facility ID | 1523 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Comments | by Primary Physician |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Comments | by Primary Care |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Nina Lucinda Jones Terry |
| Title | Md. JD |
| nterry@uabmc.edu | |
| Phone | (256)-453-6958 |
| User ID | Nina Terry |
| Facility ID | 1116 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| Comments | USPSTF criteria and VA National Lung Cancer Screening Directive |
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Comments | Shared decision making made by primary care prior to referral for enrollment, LCS coordinators discuss with Veteran over the phone as well as mail hardcopy of risks/benefits |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Comments | Chief of Radiology is part of our Lung Cancer Screening Steering Committee |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Comments | For those LDCTs performed within our VA, we use the LungRADS algorithm; for those rural Veterans getting LDCTs from the community from facilities that do not utilize appropriate management algorithms, we discuss the cases in our Pulmonary Multidisciplinary Conference |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Comments | Biweekly Pulmonary Multidisciplinary Conference for lung nodules/abnormal imaging (attended by interventional pulmonologist, several general pulmonologist, thoracic surgey, advanced practice provider, navigator, and intermittently by chest/interventional radiologist). If LungRADS 4A,B,X referral directly for review by interventional pulmonologists; all post-biopsy cases are presented by the interventional pulmonologist for multidisciplinary discussion (surgery, med onc, rad onc, pathology, radiology,etc) with facility Tumor Board |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Comments | Every LDCT has an official review and documentation in the EHR regardless of Lung RADS score with referring provider/care team placed as an additional signer to the result |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Comments | Primary care discusses smoking cessation and shared-decision making prior to enrollment to LCS, LCS coordinators discuss with Veterans and provide smoking cessation information with hardcopies mailed to Veterans; admittedly, we do not have a robust Tobacco Cessation Program outside of these individuals |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Comments | VA National Lung Cancer Screening Platform (LCSP) |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Comments | Lung Cancer Screening Steering Committee meets monthly to review information collected in the VA National Lung Cancer Screening Platform (LCSP) |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Comments | VA National Lung Cancer Screening Platform (LCSP) collects data in the national Corporate Data Warehouse accessible by Veterans Healthcare Administration |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Comments | Interventional pulmonologist personally collecting data for monitoring |
| Name | Arjan Singh Flora, MD, DAABIP, ATSF, FACP, FCCP |
| Title | Director of Lung Cancer Screening; Interventional Pulmonologist |
| arjan.flora@va.gov | |
| Phone | (505)-265-1711 |
| User ID | Arjan Flora |
| Facility ID | 2019 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Fatima Rocco |
| Title | Lung Cancer Screening Coordinator |
| frocco@elliot-hs.org | |
| Phone | (603)-663-1833 |
| User ID | Fatima Rocco |
| Facility ID | 1850 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Fatima Rocco |
| Title | Lung Cancer Screening Coordinator |
| frocco@elliot-hs.org | |
| Phone | (603)-663-1833 |
| User ID | Fatima Rocco |
| Facility ID | 1847 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Chavalia Joan Breece |
| Title | Nurse Practitioner |
| chavalia.j.breece@gunet.Georgetown.edu | |
| Phone | (202)-444-2132 |
| User ID | Chavalia Breece |
| Facility ID | 1071 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Maurice Smith |
| Title | Medical Director Center for Chest |
| masmith@frederick.health | |
| Phone | (240)-405-4069 |
| User ID | Maurice Smith |
| Facility ID | 2018 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Comments | LNC x 20 years; Lung MDC weekly with collaborative team |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Comments | Epic Communication/Inbasket messaging |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Comments | LNC has smoking cessation program |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Comments | Thynk Health |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Comments | Thynk Health/Riverain |
| Name | Tina DeStefanis-Griffiths MSN,RN,OCN |
| Title | Lung program Adminstrator/Navigator |
| tina_destefanis-griffiths@trihealth.com | |
| Phone | (513)-853-1470 |
| User ID | Tina Destefanis-Griffiths |
| Facility ID | 1709 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Tina DeStefanis-Griffiths MSN,RN,OCN |
| Title | Lung program Administrator/Lung Navigator |
| tina_destefanis-griffiths@trihealth.com | |
| Phone | (513)-853-1470 |
| User ID | Tina Destefanis-Griffiths |
| Facility ID | 1709 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Tina DeStefanis-Griffiths MSN,RN,OCN |
| Title | Lung Program Adminstrator/Navigator |
| tina_destefanis-griffiths@trihealth.com | |
| Phone | (513)-853-1470 |
| User ID | Tina Destefanis-Griffiths |
| Facility ID | 1709 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Jenna Vivo |
| Title | Practice Manager |
| jenna.vivo@leehealth.org | |
| Phone | (239)-343-5864 |
| User ID | Jenna Vivo |
| Facility ID | 1704 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Jenna Vivo |
| Title | Practice Manager |
| jenna.vivo@leehealth.org | |
| Phone | (239)-343-5864 |
| User ID | Jenna Vivo |
| Facility ID | 1704 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jenna Vivo |
| Title | Practice Manager |
| jenna.vivo@leehealth.org | |
| Phone | (239)-343-5864 |
| User ID | Jenna Vivo |
| Facility ID | 1704 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Jeffrey Velotta, MD, FACS |
| Title | Thoracic Surgeon |
| jeffrey.b.velotta@kp.org | |
| Phone | (310)-435-8511 |
| User ID | Jeff Velotta |
| Facility ID | 1864 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jeffrey Velotta, MD, FACS |
| Title | Thoracic Surgeon |
| jeffrey.b.velotta@kp.org | |
| Phone | (310)-435-8511 |
| User ID | Jeff Velotta |
| Facility ID | 1864 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| Comments | Additional risk factors include family history of lung cancer and exposure to radon, asbestos, or other occupational hazards. Patients meet/discuss with lung cancer screening program coordinator/provider regarding to appropriateness. |
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Comments | penrad/penlung |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Comments | We monitor who were diagnosed from lung cancer from low dose CT screenings. |
| Name | Vita Balista |
| Title | Nurse Practitioner |
| vita.balista@wmchealth.org | |
| Phone | (914)-306-0274 |
| User ID | Vita Balista |
| Facility ID | 1870 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | NatalieJean Ahrens |
| Title | Oncology Nurse Navigator |
| NatalieJean.Ahrens@nmhs.org | |
| Phone | (712)-396-4118 |
| User ID | NatalieJean Ahrens |
| Facility ID | 1813 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | No |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Josh Roy |
| Title | Executive Director Cancer Center |
| Josh.Roy@infirmaryhealth.org | |
| Phone | (251)-435-6536 |
| User ID | Bob Googe |
| Facility ID | 1719 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Josh Roy |
| Title | Executive Director Cancer Center |
| Josh.Roy@infirmaryhealth.org | |
| Phone | (251)-435-6536 |
| User ID | Bob Googe |
| Facility ID | 1719 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Comments | NCCN, ASCO, CAP |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Comments | NCCN, ASCO |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Comments | ASTRO, NCCN, AMERICAN COLLEGE OF RADIOLOGY |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Comments | AMERICAN JOINT COMMISSION ON CANCER (AJCC) |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Comments | CAP, ASCO, NCCN |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Comments | TEXAS TUMOR REGISTRY, NATIONAL CANCER DATABANK |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Comments | cms |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Silvia Lopez |
| Title | Clinical Certification Director |
| si.lopez@dhr-rgv.com | |
| Phone | (956)-362-7991 |
| User ID | Silvia Lopez |
| Facility ID | 2014 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| Comments | CMS, NCCN, USPSTF |
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Silvia Lopez |
| Title | Clinical Certification Director |
| si.lopez@dhr-rgv.com | |
| Phone | (956)-362-7991 |
| User ID | Silvia Lopez |
| Facility ID | 2014 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| Comments | Self pay option ($139) for patient who do not qualify for LCS but are high risk for lung cancer |
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Comments | ACR |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Annie Lally |
| Title | Lung Cancer Screening Program Manager |
| ann_m_lally@rush.edu | |
| Phone | (312)-947-5864 |
| User ID | Hillary Knowles |
| Facility ID | 1868 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Emily Groen |
| Title | Lung Cancer Screening Program Coordinator |
| emily.groen@avera.org | |
| Phone | (605)-322-1762 |
| User ID | Emily Groen |
| Facility ID | 1871 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Chanelle Lake |
| Title | Director |
| chanelle.lake@holycrosshealth.org | |
| Phone | (301)-557-2206 |
| User ID | Chanelle Lake |
| Facility ID | 1102 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Chanelle Lake |
| Title | Director |
| chanelle.lake@holycrosshealth.org | |
| Phone | (301)-557-2206 |
| User ID | Chanelle Lake |
| Facility ID | 1101 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Comments | ACR |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Janet Cady, DNP, CRNP |
| Title | Lung Cancer Screening Program Manager |
| jcady@pennstatehealth.psu.edu | |
| Phone | (717)-531-6985 |
| User ID | Janet Cady |
| Facility ID | 1769 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Sara Kraus, DNP, FNP-BC |
| Title | Associate Director of Lung Cancer Screening |
| sara-kraus@uiowa.edu | |
| Phone | (319)-384-7618 |
| User ID | Sara Kraus |
| Facility ID | 2012 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Cassidee Kuehner |
| Title | Lung Nurse Navigator |
| cassidee.kuehner@thechristhospital.com | |
| Phone | (513)-206-1938 |
| User ID | Cassidee Kuehner |
| Facility ID | 1547 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amy Heiny |
| Title | Screening Manager |
| amy.heiny@franciscanalliance.org | |
| Phone | (317)-528-8402 |
| User ID | Amy Heiny |
| Facility ID | 1228 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amy Heiny |
| Title | Screening Manager |
| amy.heiny@franciscanalliance.org | |
| Phone | (317)-528-8402 |
| User ID | Amy Heiny |
| Facility ID | 1491 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Amy Heiny |
| Title | Screening Manager |
| amy.heiny@franciscanalliance.org | |
| Phone | (317)-528-8402 |
| User ID | Amy Heiny |
| Facility ID | 1059 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Amy Heiny |
| Title | Screening Manager |
| amy.heiny@franciscanalliance.org | |
| Phone | (317)-528-8402 |
| User ID | Amy Heiny |
| Facility ID | 1059 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amy Heiny |
| Title | Screening Manager |
| amy.heiny@franciscanalliance.org | |
| Phone | (317)-528-8402 |
| User ID | Amy Heiny |
| Facility ID | 1059 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amy Heiny |
| Title | Screening Manager |
| amy.heiny@franciscanalliance.org | |
| Phone | (317)-528-8402 |
| User ID | Amy Heiny |
| Facility ID | 1553 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amy Heiny |
| Title | Screening Manager |
| amy.heiny@franciscanalliance.org | |
| Phone | (317)-528-8402 |
| User ID | Amy Heiny |
| Facility ID | 1490 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Cassidee Kuehner |
| Title | Lung Health Nurse Navigator` |
| cassidee.kuehner@thechristhospital.com | |
| Phone | (513)-206-1938 |
| User ID | Cassidee Kuehner |
| Facility ID | 1547 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Cassidee Kuehner |
| Title | Lung Health Nurse Navigator` |
| cassidee.kuehner@thechristhospital.com | |
| Phone | (513)-206-1938 |
| User ID | Cassidee Kuehner |
| Facility ID | 1547 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Cassidee Kuehner |
| Title | RN |
| cassidee.kuehner@thechristhospital.com | |
| Phone | (513)-206-1938 |
| User ID | Cassidee Kuehner |
| Facility ID | 1547 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Comments | via Nuance |
| Name | katie |
| Title | Program Coordinator |
| kratcliff@iuhealth.org | |
| Phone | (317)-605-8021 |
| User ID | katie ratcliff |
| Facility ID | 2009 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Kim Bayer |
| Title | Radiology Nurse/Lung Screening Coordinator |
| kscheper@mhhcc.org | |
| Phone | (812)-996-7325 |
| User ID | Erin Whaley |
| Facility ID | 1357 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brett Bade |
| Title | Director Lung Cancer Screening Program |
| bbade@northwell.edu | |
| Phone | (212)-794-2800 |
| User ID | Kristina Sopp |
| Facility ID | 1295 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brett Bade |
| Title | Director Lung Cancer Screening Program |
| bbade@northwell.edu | |
| Phone | (212)-794-2800 |
| User ID | Kristina Sopp |
| Facility ID | 1342 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brett Bade |
| Title | Director Lung Cancer Screening Program |
| bbade@northwell.edu | |
| Phone | (212)-794-2800 |
| User ID | Kristina Sopp |
| Facility ID | 1292 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brett Bade |
| Title | Director Lung Cancer Screening Program |
| bbade@northwell.edu | |
| Phone | (212)-794-2800 |
| User ID | Kristina Sopp |
| Facility ID | 1291 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brett Bade |
| Title | Director Lung Cancer Screening Program |
| bbade@northwell.edu | |
| Phone | (212)-794-2800 |
| User ID | Kristina Sopp |
| Facility ID | 1471 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brett Bade |
| Title | Director Lung Cancer Screening Program |
| bbade@northwell.edu | |
| Phone | (212)-794-2800 |
| User ID | Kristina Sopp |
| Facility ID | 1470 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brett Bade |
| Title | Director Lung Cancer Screening Program |
| bbade@northwell.edu | |
| Phone | (212)-794-2800 |
| User ID | Kristina Sopp |
| Facility ID | 1290 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brett Bade |
| Title | Director Lung Cancer Screening Program |
| bbade@northwell.edu | |
| Phone | (212)-794-2800 |
| User ID | Kristina Sopp |
| Facility ID | 1289 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brett Bade |
| Title | Director Lung Cancer Screening Program |
| bbade@northwell.edu | |
| Phone | (212)-794-2800 |
| User ID | Kristina Sopp |
| Facility ID | 1288 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brett Bade |
| Title | Director Lung Cancer Screening Program |
| bbade@northwell.edu | |
| Phone | (212)-794-2800 |
| User ID | Kristina Sopp |
| Facility ID | 1285 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brett Bade |
| Title | Director Lung Cancer Screening Program |
| bbade@northwell.edu | |
| Phone | (212)-794-2800 |
| User ID | Kristina Sopp |
| Facility ID | 1284 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brett Bade |
| Title | Director Lung Cancer Screening Program |
| bbade@northwell.edu | |
| Phone | (212)-794-2800 |
| User ID | Kristina Sopp |
| Facility ID | 1282 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Lauren Moore |
| Title | CRNP Thoracic oncology program coordinator |
| lauren.moore@tidalhealth.org | |
| Phone | (410)-543-7551 |
| User ID | Lauren Moore |
| Facility ID | 1816 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Lauren Moore |
| Title | CRNP, Thoracic Oncology Program Coordinator |
| lauren.moore@tidalhealth.org | |
| Phone | (410)-543-7551 |
| User ID | Lauren Moore |
| Facility ID | 1817 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jeffrey Nolter |
| Title | Director of Imaging Services |
| Jeffrey.Nolter@evanhospital.com | |
| Phone | (570)-522-4045 |
| User ID | Jeffrey Nolter |
| Facility ID | 1955 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Katelyn Grados |
| Title | Lung Screening Coordinator |
| Kmg0322@mountnittany.org | |
| Phone | (814)-231-6881 |
| User ID | Katelyn Grados |
| Facility ID | 1559 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Cari Williams |
| Title | Oncology Navigator |
| cari.williams@imail.org | |
| Phone | (406)-238-6302 |
| User ID | Cari Williams |
| Facility ID | 1583 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Meghan Pimley |
| Title | Director of Oncology |
| meghan.pimley@imail.org | |
| Phone | (406)-238-6898 |
| User ID | Cari Williams |
| Facility ID | 1583 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Cari Williams |
| Title | Oncology Nurse Navigator |
| cari.williams@imail.org | |
| Phone | (406)-238-6302 |
| User ID | Cari Williams |
| Facility ID | 1583 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Arlyn Arseneaux |
| Title | Direcor of Cancer Services |
| aarseneaux@stph.org | |
| Phone | (985)-338-5018 |
| User ID | Megan Broussard |
| Facility ID | 1299 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Megan S Broussard |
| Title | Lung Cancer Screening Coordinator |
| mbroussard@stph.org | |
| Phone | (985)-871-5864 |
| User ID | Megan Broussard |
| Facility ID | 1299 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Nikki Audia |
| Title | Lung Navigator |
| cerissa_audia@physiciansregional.com | |
| Phone | (239)-348-4401 |
| User ID | Nikki Audia |
| Facility ID | 1891 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Nikki Audia |
| Title | Lung Navigator |
| cerissa_audia@physiciansregional.com | |
| Phone | (239)-348-4401 |
| User ID | Nikki Audia |
| Facility ID | 1891 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Nikki Audia |
| Title | Lung Navigator |
| cerissa_audia@physiciansregional.com | |
| Phone | (239)-348-4401 |
| User ID | Nikki Audia |
| Facility ID | 1891 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens |
|---|